,Target Name,"Target, Subunit, Species",Target Mutant/Chimera Details,Target Species (Bioactivity),Substance Action on Target,Substance Effect,Bioassay Category,Bioassay Name,Bioassay Details,Biological Species/NCBI ID,Medchem: Measurement Parameter,Unit,Qualitative value,Quantitative value,References,Canomical_Smiles,pChEMBL
232,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCNCC1,1
230,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.11,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCC(N2CCN(C)CC2)CC1,1
231,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.22,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C(C)C)CC1,1
149,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.26,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
237,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.26,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1C1CCNCC1,1
219,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.31,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,C#Cc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
242,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.32,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1C1CCN(CCO)CC1,1
165,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.49,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1C1CCN(C)CC1,1
196,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,0.51,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",COc1cc(N2CCN(C)CC2)c2cc1Nc1ncc(Cl)c(n1)Nc1cc(ccc1N(C)S(C)(=O)=O)CC2,1
238,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.52,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1C1CCN(C)CC1,1
169,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.62,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1C1CCN(CCO)CC1,1
225,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.67,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,C#Cc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCC3)c2cc1N1CCN(C)CC1,1
228,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.7,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCC(N2CCOCC2)CC1,1
240,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.77,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1C1CCN(C(C)C)CC1,1
241,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.78,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1C1CCN(C2CCOCC2)CC1,1
157,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,0.79,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCCOc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
2616,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCOCC4)CC3)cc2OC)ncc1Cl,1
2624,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCCCC4)CC3)ccc2OC)ncc1Cl,1
2629,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)cc2OC)ncc1Cl,1
2628,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(NC(C)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC2CCC2)n1,1
2609,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CCCCC2)n1,1
2627,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2610,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCOCC3)cc2OC)ncc1Cl,1
2626,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2611,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCCC(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2625,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2623,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCCC2)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2612,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(=O)CC)CC3)cc2OC)ncc1Cl,1
2617,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN3CCOC[C@H]3C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2622,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2621,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCC3CCCN(C)C3)cc2OC)ncc1Cl,1
2613,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2620,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2614,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2619,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCOCC3)cc2OC)ncc1Cl,1
2615,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC2CCCC2)n1,1
2618,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CCCC2)n1,1
2570,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2ccn3CCCN2CCOCC2)ncc1Cl,1
2604,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@@H](C(N)=O)C3)cc2OC)ncc1Cl,1
2608,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC2CCC2)n1,1
2594,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(CC)CC)n3)c(OC)c2)C1,1
2583,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(NCCN3CCOCC3)cc2OC)ncc1Cl,1
2584,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCCN3CCOCC3)ccc2OC)ncc1Br,1
2585,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2586,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(C(N)=O)CC3)cc2OC)ncc1Br,1
2587,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2588,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCCC(C(N)=O)C3)cc2OC)ncc1Cl,1
2589,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2590,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(F)ccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2591,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)NC(C)C)n2)ccc(OC2CCN(C)CC2)c1F,1
2592,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@@H](C(N)=O)C3)cc2OC)ncc1Cl,1
2593,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCCN3CCOCC3)cc2OC)ncc1Br,1
2595,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(C(=O)NC)CC3)cc2OC)ncc1Cl,1
2607,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCCN3CCN(C)CC3)cc2OC)ncc1Br,1
2596,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2ccn3CCCN2CCOCC2)ncc1Br,1
2597,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)C(C)(C)C3)cc2OC)ncc1Cl,1
2598,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOCCOC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)c(OC)c2)CC1,1
2599,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OCCN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2600,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCCC(C(N)=O)C3)ccc2OC)ncc1Cl,1
2601,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCC4)CC3)cc2OC)ncc1Cl,1
2602,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCCC(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2603,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC[C@@H](C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2631,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCC4)CC3)cc2OC)ncc1Cl,1
2605,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@H](C(N)=O)C3)cc2OC)ncc1Cl,1
2606,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2ccn3CCCN2CCN(C)CC2)ncc1Cl,1
2630,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCCCC4)CC3)ccc2OC)ncc1Cl,1
2639,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCC4)CC3)cc2OC)ncc1Cl,1
2632,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCN(C)CC3)cc2OC)ncc1Cl,1
2633,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCCC2)ccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2662,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN5CCOC[C@H]5C4)c4c3C(=O)N(C)C4)n2)c(OC)c1,1
2663,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c3c2C(=O)N(C)CC3)n1,1
2664,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCNCC3)c3c2C(=O)N(C)CC3)n1,1
2665,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Br,1
2666,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN3CCOC[C@H]3C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,1
2667,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1ccc(Nc2ncc3ccn(-c4cccc(Cl)c4)c3n2)c(C)c1,1
2668,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccc(-c2ccncc2)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,1
2447,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c(OC)c2)C1,1
2446,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCN(CCO)c1ccc(Nc2ncc(Br)c(Nc3ccccc3S(=O)(=O)NC)n2)c(C)c1,1
2445,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2C(=O)NC(C)C)n1,1
2444,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2443,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2442,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2441,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCN1CCC(Oc2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC)n3)c(OC)c2)C1,1
2440,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC1CCN(c2ccc(OC)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC)n3)c2)C1,1
2439,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(O)C3)cc2OC)ncc1Cl,1
2438,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(NC(C)(C)CO)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2437,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCNCC3)cc2OC)ncc1Br,1
2436,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1ccc(N2CCOCC2)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2435,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Br,1
2434,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N(C)C)C3)cc2OC)ncc1Cl,1
2433,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2C)ncc1Br,1
2432,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2431,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(NC)C3)cc2OC)ncc1Cl,1
2430,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCSCC3)cc2OC)ncc1Br,1
2661,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCC(C4CCN(C(=O)OC(C)(C)C)CC4)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,1
2660,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2nc(Cl)ncc2Cl)c2c1CCN(C)C2=O,1
2659,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCOCC2)ccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2645,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCN(CC)C(=O)C1CCCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,1
2634,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCN(C(C)=O)CC3)ccc2OC)ncc1Cl,1
2635,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2636,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2637,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCN(C)CC4)CC3)ccc2OC)ncc1Cl,1
2638,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2581,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OCCN2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2640,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)cc2OC)ncc1Cl,1
2641,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCN(C)CC4)CC3)ccc2OC)ncc1Cl,1
2642,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC[C@H]2CN2CCCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2643,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1c(C)cccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2644,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(CC(=O)NC(C)C)CC3)cc2OC)ncc1Cl,1
2646,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2658,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2647,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCCCC4)CC3)ccc2OC)ncc1Cl,1
2648,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCCC2)ccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2649,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCOCC4)CC3)ccc2OC)ncc1Cl,1
2650,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCCCC4)CC3)ccc2OC)ncc1Cl,1
2651,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,1
2652,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2653,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(F)ccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2654,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2655,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCN(C)CC4)CC3)ccc2OC)ncc1Cl,1
2656,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2657,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2582,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@H](C(N)=O)C3)cc2OC)ncc1Cl,1
2580,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N2CCOCC2)n1,1
2428,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCCCC3)ccc2C)ncc1Br,1
2484,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C)CC3)ccc2OC)ncc1Cl,1
2486,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N(C)C)C3)ccc2OC)ncc1Cl,1
2487,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2488,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2489,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC3CCN(C)CC3)ccc2OC)ncc1Br,1
2490,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(N3CCOCC3)cc2OC)ncc1Cl,1
2491,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N(C)C)C3)cc2OC)ncc1Cl,1
2492,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)c2ccccc2)n1,1
2493,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2494,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCNCC3)cc2OC)ncc1Br,1
2495,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(NCC(C)(C)CO)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2496,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)N3CCOCC3)ccc2C)ncc1Br,1
2497,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2498,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,1
2499,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1c(C)cccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2500,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2501,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c(OC)c2)CC1,1
2502,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCOCC3)ccc2OC)ncc1Cl,1
2503,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCNC(=O)C3)cc2OC)ncc1Cl,1
2504,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Cl,1
2505,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2506,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCC3CCN(C)CC3)cc2OC)ncc1Cl,1
2507,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2508,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(O)CC3)ccc2OC)ncc1Cl,1
2509,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(C#N)CC3)cc2OC)ncc1Br,1
2510,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2511,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(NC(C)=O)C3)cc2OC)ncc1Cl,1
2512,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2513,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,1
2514,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCS(=O)(=O)CC3)cc2OC)ncc1Br,1
2485,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c(OC)c2)CC1,1
2483,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(O)CC3)ccc2OC)ncc1Cl,1
2516,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2482,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCOCC2)ccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2453,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(O)CC3)cc2OC)ncc1Cl,1
2454,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Cl,1
2455,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OC2CCN(C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2456,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2457,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2F)ncc1Cl,1
2458,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(OC)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2459,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2460,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(NC)C3)ccc2OC)ncc1Cl,1
2461,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC)n3)c(OC)c2)C1,1
2462,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2463,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOc1ccc(-c2ccc(OC)cc2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2464,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2465,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C)CC3)ccc2OC)ncc1Cl,1
2466,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)CC(C)C)n1,1
2467,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2468,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C)CC3)ccc2OC)ncc1Br,1
2469,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)CC3)n1,1
2470,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(NC)C3)cc2OC)ncc1Cl,1
2471,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Br,1
2472,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OCC3CCN(C)CC3)cc2OC)ncc1Cl,1
2473,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C)C(=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2474,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC3CCNCC3)ccc2OC)ncc1Br,1
2475,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOc1cc(N2CCOCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2476,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOc1ccc(N2CCOCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2477,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(F)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2478,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N(CCOC)CCOC)cc2OC)ncc1Br,1
2479,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2OC)ncc1Cl,1
2480,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)CCC(C)C)n1,1
2481,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(NC)C3)ccc2OC)ncc1Cl,1
2515,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2517,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCOCC3)cc2OC)ncc1Cl,1
2579,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN3COCC[C@H]3C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2548,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)NC3CCCCC3)ccc2C)ncc1Br,1
2550,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCOc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2551,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)CC(C)C)n1,1
2552,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCOCC3)ccc2OC)ncc1Br,1
2553,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCCC(C(N)=O)C3)cc2OC)ncc1Cl,1
2554,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)NC(C)C)n2)ccc(N2CCOCC2)c1F,1
2555,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(OCCOC)CC3)cc2OC)ncc1Cl,1
2556,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2OC)ncc1Cl,1
2557,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2558,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(CN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2559,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CCCC2)n1,1
2560,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Cl,1
2561,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Cl,1
2562,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(C(N)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2563,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)C3)cc2OC)ncc1Cl,1
2564,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2565,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCCC(C(N)=O)C3)cc2OC)ncc1Cl,1
2566,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)Cc2ccccc2)n1,1
2567,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2568,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(NC)C3)cc2OC)ncc1Cl,1
2569,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(NC(C)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2448,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C(C)C)C3)cc2OC)ncc1Cl,1
2571,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN4CCOC[C@H]4C3)cc2OC)ncc1Cl,1
2572,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN4CCOC[C@@H]4C3)cc2OC)ncc1Cl,1
2573,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC[C@H](C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2574,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC[C@@H](C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2575,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCOCC3)cc2F)ncc1Cl,1
2576,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCCC3=O)cc2OC)ncc1Cl,1
2577,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(CC)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2578,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2F)C1,1
2549,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C(C)=O)CC3)cc2OC)ncc1Br,1
2547,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(CO)CC3)cc2OC)ncc1Cl,1
2518,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,1
2546,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)N3CCN(C)CC3)ccc2OC)ncc1Br,1
2519,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)CC3)cc2F)ncc1Cl,1
2520,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(O)CC3)cc2OC)ncc1Cl,1
2521,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCC3CCN(C)CC3)ccc2OC)ncc1Cl,1
2522,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1cc(F)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2523,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2cccc3c2ccn3C)ncc1Cl,1
2524,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,1
2450,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2449,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C)CC3)ccc2OC)ncc1Cl,1
2525,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)N3CCNCC3)ccc2C)ncc1Br,1
2526,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2527,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Cl,1
2528,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(NCC(C)(C)CN(C)C)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2529,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2530,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)c3c2ccn3C)ncc1Cl,1
2531,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)C)CC3)cc2OC)ncc1Cl,1
2532,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCN(C)CC3)cc2OC)ncc1Cl,1
2533,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OCC2CCCCN2C)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2534,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(CCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2535,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2C(=O)N2CCCC2)n1,1
2536,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CC(C)N(C(C)=O)C(C)C3)cc2OC)ncc1Cl,1
2537,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCN(C)CC3)ccc2OC)ncc1Cl,1
2538,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCN1Cc2cccc(Nc3nc(Nc4ccc(N5CCN(C)CC5)cc4OC)ncc3Cl)c2C1=O,1
2539,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(NC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2540,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(C(N)=O)CC3)cc2OC)ncc1Cl,1
2541,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCCC(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2542,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OCCCN3CCOCC3)cc2C)ncc1Br,1
2543,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC2CCC2)n1,1
2544,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)ncc1Br,1
2545,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCCC(C(N)=O)C3)cc2OC)ncc1Cl,1
2429,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Cl,1
2417,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(F)(F)F)n1,1
2427,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(OC)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2346,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCCC(C(N)=O)C3)cc2OC)ncc1Br,1
2354,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NC5CCC5)c4)c3n2)cc(OC)c1OC,1
2353,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(Cc5nnnn5C)c4)c3n2)cc(OC)c1OC,1
2352,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(=O)NC)CC3)cc2OC)ncc1Cl,1
2351,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC2CCCC2)n1,1
2350,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C(=O)C(C)C)CC3)cc2OC)ncc1Cl,1
2349,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N(C)C(C)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2348,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@@H](C(N)=O)C3)cc2OC)ncc1Cl,1
2347,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(C(N)=O)CC3)cc2OC)ncc1Cl,1
2345,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,1
2356,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C(C)C)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,1
2344,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OCC2CCCN(C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2343,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1cc(F)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Br,1
2342,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl,1
2341,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OCC(C)(C)CN(C)C)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2340,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2339,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c(OC)c2)CC1,1
2338,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,1
2337,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2355,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(n2)N(c2cccnc2)CCC3)cc(OC)c1OC,1
2357,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,1
2335,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(C)(=O)=O)n1,1
2368,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(F)ccc2OC)ncc1Br,1
2376,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(F)ccc2OC)ncc1Cl,1
2375,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2ccn3C)ncc1Cl,1
2374,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccccc2OC(F)F)ncc1Cl,1
2373,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(F)ccc2Cl)ncc1Br,1
2372,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2OC)ncc1Br,1
2371,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2370,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(F)ccc2F)ncc1Br,1
2369,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2Cl)ncc1Br,1
2367,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Br,1
2358,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(F)c(F)cc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2366,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNc1ccccc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2426,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)C3)cc2OC)ncc1Br,1
2364,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C)cc2F)ncc1Br,1
2363,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2C)ncc1Br,1
2362,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C)cc2C)ncc1Br,1
2361,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccccc2OC)ncc1Br,1
2360,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(C)(=O)=O)n1,1
2359,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccccc2C)ncc1Br,1
2336,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3ccc(OC)cc3)ccc2OC)ncc1Br,1
2334,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(-n3ccnc3C)cc2OC)ncc1Br,1
2378,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2F)ncc1Br,1
2302,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2310,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,1
2309,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(F)ccc2OC)ncc1Br,1
2308,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC#N)c4)c3n2)cc(OC)c1OC,1
2307,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCNCC3)c3c2C(=O)N(C)C3)n1,1
2306,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2305,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Br,1
2304,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCNCC3)cc2OC)ncc1Cl,1
2301,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc([N+](=O)[O-])ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2312,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2300,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2299,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Br,1
2298,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,1
2297,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Br,1
2296,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Br,1
2295,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2294,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
7,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound against human mutant Anaplastic lymphoma kinase (ALK F1174L) was determined,human,IC50,nM,=,1.0,"Article; Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko; Cancer Cell; vol. 19; 5; (2011); p. 679 - 690;",CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,1
2311,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br,1
2313,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,1
2333,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2CCC3)ncc1Br,1
2324,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCNCC3)cc2OC)ncc1Cl,1
2332,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2OC)ncc1[N+](=O)[O-],1
2331,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(N(C)C)c2C)ncc1Br,1
2330,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3cn[nH]c23)ncc1Br,1
2329,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2328,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(N)c2C1=O,1
2327,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCCCC4)CC3)cc2OC)ncc1Cl,1
2326,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)cc2OC)ncc1Cl,1
2325,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC3CCN(C(C)=O)CC3)ccc2OC)ncc1Br,1
2323,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1ccc(F)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,1
2314,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(n2)N(c2ccccn2)CC3)cc(OC)c1OC,1
2322,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,NS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2OC(F)(F)O3)ncc1Br,1
2321,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC)cc2OC)ncc1Br,1
2320,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN(C)C)c4)c3n2)cc(OC)c1OC,1
2319,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(n2)N(c2ccccn2)C(=O)CC3)cc(OC)c1OC,1
2318,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4CO)c3n2)cc(OC)c1OC,1
2317,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC#N)c4)c3n2)cc(OC)c1OC,1
2316,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccnc(Cl)c4)c3n2)cc(OC)c1OC,1
2315,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(n2)N(c2ccccn2)C(=O)C3)cc(OC)c1OC,1
2377,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(OC)c2OC)ncc1Br,1
2365,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C)cc2OC)ncc1Br,1
2452,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1c(C)cccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,1
2383,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(Cl)ccc2OC)ncc1Br,1
2392,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)cc2C)ncc1Cl,1
2391,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)cc2C)ncc1Br,1
2390,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2412,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3cccnc3)ccc2OC)ncc1Br,1
2389,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCCc1ccccc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2388,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,1
2387,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N(C)C)ccc2OC)ncc1Br,1
2413,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3ccccn3)ccc2OC)ncc1Br,1
2414,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2OCCO)ncc1Br,1
2386,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C)cc(C)c2C)ncc1Br,1
2409,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOc1ccc(OCC)c(Nc2ncc(Br)c(Nc3ccccc3S(=O)(=O)NC)n2)c1,1
2416,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3cccc(OC)c3)ccc2C)ncc1Br,1
2385,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2OCC3)ncc1Cl,1
2451,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N(C)C)C3)ccc2OC)ncc1Cl,1
2384,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cccc3[nH]ccc23)ncc1Cl,1
2393,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(OC)ccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2394,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(-n3ccnc3)cc2OC)ncc1Br,1
2395,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(-n2cncn2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2404,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2OC(F)(F)O3)ncc1Br,1
2408,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3c2CCCC3)ncc1Br,1
2410,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(-n2cncn2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,1
2407,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCCOc1ccc(OC)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2411,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3ccncc3)ccc2OC)ncc1Br,1
2406,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,1
2405,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3ccccc3)ccc2OC)ncc1Br,1
2403,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Cl,1
2396,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOc1ccc(OC)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2402,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3ccncc3)ccc2C)ncc1Br,1
2401,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(OC)c(OC)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2400,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(-n3cncn3)cc2OC)ncc1Cl,1
2399,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1cc(F)ccc1Nc1nc(Nc2cccc3c2ccn3C)ncc1Cl,1
2398,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccccc2OC(F)(F)F)ncc1Cl,1
2397,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2OC(C)C)ncc1Br,1
2418,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(-c3ccc(OC)cc3)ccc2C)ncc1Br,1
2415,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)ccc2OCCOC)ncc1Br,1
2382,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC)nc2OC)ncc1Br,1
2423,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Cl,1
2420,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCOc1ccc(-c2ccccc2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC)n1,1
2381,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(F)cc2OC)ncc1Br,1
2421,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N2CCOCC2)n1,1
2425,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC3CCN(C)C3)cc2OC)ncc1Cl,1
2419,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2C(=O)N(C)C)n1,1
2379,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc3[nH]ccc23)ncc1Br,1
2424,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
2380,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(C)C)ccc2C)ncc1Br,1
2422,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,=,0.001,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,Cc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1
151,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)Cc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
229,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C2COC2)CC1,1
180,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)n1c2cc(N3CCN(C)CC3)c(Br)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
168,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.3,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1C1CCN(C2CCOCC2)CC1,1
2013,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (Disssolved in DMSO) against human recombinant wild type ALK upon incubation in presence of 30 uM ATP in 50 mM HEPES, pH 7.0 for 90 mins at RT was determined by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) FRET ASSAY",NaN,IC50,nM,=,1.4,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; WO2015/50989; (2015); A2;,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)OCCOc2ccc(F)cc21,1
160,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.4,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCCCOc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
182,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,C=Cc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
430,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,1.5,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",COc1cc(N2CCN(C)CC2)c2cc1Nc1ncc(Cl)c(n1)Nc1cc(ccc1S(=O)(=O)C(C)C)CC2,1
23,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,1
212,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.6,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)n1c2cc(N3CCN(C)CC3)c(OC(F)F)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
249,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.8,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCC3)c2cc1N1CCN(C)CC1,1
209,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1.9,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(CC)c2cc1N1CCN(C)CC1,1
92,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,2.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCN(C)CC1,1
97,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,2.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCN(C(C)C)CC1,1
71,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,2.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCNCC1,1
234,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.0,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCOc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1CCN(C)CC1,1
69,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,2.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCN(CCN(C)C)CC1,1
233,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.3,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCOCC1,1
167,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1C1CCN(C(C)C)CC1,1
244,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCOc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1CCC(N2CCOCC2)CC1,1
239,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.6,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1C1CCN(C2COC2)CC1,1
161,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.6,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1CCN(C)CC1,1
183,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,2.9,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
2152,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5% DMSO) against human ALK upon incubation in presence of 1 uM ATP using 20 mM Hepes buffer , pH 7.2 for 15 min at 37 degree C",human,IC50,nM,=,2.9,"Article; Mesaros, Eugen F.; Thieu, Tho V.; Wells, Gregory J.; Zificsak, Craig A.; Wagner, Jason C.; Breslin, Henry J.; Tripathy, Rabindranath; Diebold, James L.; McHugh, Robert J.; Wohler, Ashley T.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Huang, Zeqi; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin J.; Aimone, Lisa D.; Cheng, Mangeng; Ator, Mark A.; Ott, Gregory R.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 115 - 125;",COc1cc(C2CCN(C[C@H](O)CF)CC2)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,1
127,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,3.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",CC(C)S(=O)(=O)c1nn(C)cc1Nc1nc(Nc2cc(F)c(C3CCN(C)CC3)cc2OC2CC2)ncc1Cl,1
125,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,3.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",CC(C)S(=O)(=O)c1nn(C)cc1Nc1nc(Nc2ccc(C3CCN(C)CC3)cc2OC2CC2)ncc1Cl,1
109,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,3.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCCN(C)C1,1
428,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,3.1,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",COc1ccc2cc1Nc1nc(ncc1Cl)Nc1ccc(N3CCN(C)CC3)c(c1)CC2,1
55,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (dissolved in DMSO) against human ANAPLASTIC LYMPHOMA KINASE expressed in baculovirus upon incubation in 20 mM HEPES buffer, pH 7.2 using 10 ug/ml GST-PLC-GAMMA as subatrate in presence of 1 uM ATP at 37 degree C for 15 minutes by TIME RESOLVED FLUORESCENCE (TRF) ASSAY",human,IC50,nM,=,3.1,"Article; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 10; (2012); p. 4580 - 4593;",COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC(N1CCN(C)CC1)CC2,1
1075,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against mutant (L1196M) human ALK kinase in presence of 30 uM ATP upon incubation in 50 mM HEPES, pH 7.5 for 45 min at 25 degree C",NaN,IC50,µM,=,0.0033,Patent; HANSOH PHARMACEUTICAL GROUP CO LTD; WO2015/81813; (2015); A1;,Cc1cc(Nc2ncc(Cl)c(Nc3cccnc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCN2CCOCC2)CC1,1
142,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,3.4,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)Oc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
745,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound (dissolved in DMSO) against recombinant human GST-ANAPLASTIC LYMPHOMA KINASE expressed in Sf-21 insect cells in presence of 1 uM ATP upon incubation in 20 mM HEPES, pH 7.2 at 35 degree C for 15 min by ELISA",human,IC50,nM,=,3.4,Article; Antonia F. Stepan; Vincent Mascitti; Kevin Beaumont; Amit S. Kalgutkar; MedChemComm; vol. 4; 4; (2013); p. 631 - 652;,COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,1
429,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,3.4,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",CN1CCN(c2ccc3cc2CCc2ccc(N(C)S(C)(=O)=O)c(c2)Nc2nc(ncc2Cl)N3)CC1,1
227,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,3.6,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCC3)c2c(F)c1N1CCN(C)CC1,1
56,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (dissolved in DMSO) against human ANAPLASTIC LYMPHOMA KINASE expressed in baculovirus upon incubation in 20 mM HEPES buffer, pH 7.2 using 10 ug/ml GST-PLC-GAMMA as subatrate in presence of 1 uM ATP at 37 degree C for 15 minutes by TIME RESOLVED FLUORESCENCE (TRF) ASSAY",human,IC50,nM,=,4.0,"Article; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 10; (2012); p. 4580 - 4593;",COCCNC1CCc2cc(Nc3ncc(Cl)c(N[C@H]4[C@@H](C(N)=O)[C@@H]5C=C[C@H]4C5)n3)c(OC)cc2CC1,1
111,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,1
1862,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against N-terminal GST- tagged recombinant human Anaplastic lymphoma kinase expressed in insect cells using 250 uM KKKSPGEYVNIEFG as substrate and in presence of 10 mM [GAMMA-33P]ATP upon incubation in 8 mM MOPS buffer, pH 7.0 for 40 minutes at RT",NaN,IC50,µM,=,0.004,Patent; ASTRAZENECA PLC; WO2012/17239; (2012); A2;,COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(Cl)c(-c2c[nH]c3ccccc23)n1.O=C(O)C(F)(F)F,1
138,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human mutant (L1196M) ALK kinase in presence of 5 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)C1,1
135,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNC1,1
133,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CNC1,1
162,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,4.0,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1CCC(N2CCOCC2)CC1,1
129,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",CC(C)S(=O)(=O)c1nn(C)cc1Nc1nc(Nc2cc(Cl)c(C3CCN(C)CC3)cc2OC2CC2)ncc1Cl,1
99,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",COCCN1CCC(c2cc(OC3CC3)c(Nc3ncc(Cl)c(Nc4cn(C)nc4S(=O)(=O)C(C)C)n3)cc2C)CC1,1
107,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,4.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",CCNC(=O)N1CCC(c2cc(OC3CC3)c(Nc3ncc(Cl)c(Nc4cn(C)nc4S(=O)(=O)C(C)C)n3)cc2C)CC1,1
172,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,4.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCCC3)c2cc1N1CCN(C)CC1,1
2004,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound (dissolved in 2% DMSO) against recombinant human mutant anaplastic lymphoma kinase L1196M (0.5 nM) expressed in baculovirus using 3 uM 5-FAM-KKSRGDYMTMQIG-CONH2 as substrate upon incubation in 25 mM Hepes, pH 7.1 for 1 hr at RT in presence of 51 uM ATP",NaN,IC50,nM,=,5.0,"Article; Lu, Xiaoyun; Ding, Ke; Journal of Medicinal Chemistry; vol. 57; 4; (2014); p. 1167 - 1169;",C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1cc(F)ccc1Cl,1
73,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against mutant (L1196M) human ALK kinase in presence of 30 uM ATP upon incubation in 50 mM HEPES, pH 7.5 for 45 min at 25 degree C",NaN,IC50,µM,=,0.005,Patent; HANSOH PHARMACEUTICAL GROUP CO LTD; WO2015/81813; (2015); A1;,Cc1cc(Nc2ncc(Cl)c(Nc3cccnc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,1
746,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,5.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",COc1cc(N2CCN(C)CC2)c2cc1Nc1ncc(Cl)c(n1)Nc1cccc(c1)CC2,1
170,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,5.3,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
173,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,5.4,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCCCC3)c2cc1N1CCN(C)CC1,1
166,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,5.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1C1CCN(C2COC2)CC1,1
159,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,5.8,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)n1c2[nH]c3cc(C#N)ccc3c2c(=O)c2ccc(N3CCN(C)CC3)c(F)c21,1
236,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,5.8,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)Oc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1CCN(C)CC1,1
1064,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against N-terminal GST- tagged recombinant human Anaplastic lymphoma kinase expressed in insect cells using 250 uM KKKSPGEYVNIEFG as substrate and in presence of 10 mM [GAMMA-33P]ATP upon incubation in 8 mM MOPS buffer, pH 7.0 for 40 minutes at RT",NaN,IC50,µM,=,0.006,Patent; ASTRAZENECA PLC; WO2012/17239; (2012); A2;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(-c2c[nH]c3ccccc23)n1,1
2146,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound aganist N-terminal GST-tagged recombinant human ALK (0.4 nM) expressed in insect cells using 1.5 uM SRCtide substrate, 5 mM ATP upon incubation in 50 mM HEPES, pH 7.3 for 90 min at RT",human,IC50,µM,=,0.006,Patent; ASTRAZENECA PLC; WO2009/16410; (2009); A3;,CC(=O)N[C@H]1CCN(c2nc(Nc3cc(C)[nH]n3)nc(N[C@@H](C)c3ncc(F)cn3)n2)C1,1
2005,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human ALK upon incubation using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP in 8 mM MOPS buffer, pH 7.0 for 40 mins at RT",NaN,IC50,nM,=,6.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2014/89324; (2014); A1;,C[C@@H](Oc1cc(-c2ccc3c(c2)CCNC3)cnc1N)c1c(Cl)ccc(F)c1Cl,1
58,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (dissolved in DMSO) against human ANAPLASTIC LYMPHOMA KINASE expressed in baculovirus upon incubation in 20 mM HEPES buffer, pH 7.2 using 10 ug/ml GST-PLC-GAMMA as subatrate in presence of 1 uM ATP at 37 degree C for 15 minutes by TIME RESOLVED FLUORESCENCE (TRF) ASSAY",human,IC50,nM,=,6.0,"Article; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 10; (2012); p. 4580 - 4593;",COc1cc2c(cc1Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)CCC(N1CCOCC1)CC2,1
2291,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound (dissolved in DMSO) against recombinant human GST-ANAPLASTIC LYMPHOMA KINASE expressed in Sf-21 insect cells in presence of 1 uM ATP upon incubation in 20 mM HEPES, pH 7.2 at 35 degree C for 15 min by ELISA",human,IC50,nM,=,6.0,Article; Antonia F. Stepan; Vincent Mascitti; Kevin Beaumont; Amit S. Kalgutkar; MedChemComm; vol. 4; 4; (2013); p. 631 - 652;,COc1cc(N2CCN(CC(N)=O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,1
119,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,6.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(F)(F)F)cc1C1CCN(C)CC1,1
176,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,6.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCCC(C)n1c2cc(N3CCN(C)CC3)c(OC)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
143,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,6.6,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)n1c2[nH]c3cc(C#N)ccc3c2c(=O)c2cc(F)c(N3CCN(C)CC3)c(F)c21,1
2292,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against HUMAN ALK upon incubation in 8 mM MOPS, pH 7 for 40 mins at RT in presence of 10 uM [GAMMA-33P]ATP using 250 uM KKKSPGEYVNIEFG as substrate",NaN,IC50,nM,=,7.0,Patent; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; CALITOR SCIENCES LLC; WO2014/193647; (2014); A2;,N#C/C(=C/c1c[nH]c2ncc(-c3cnn(C4CCNCC4)c3)cc12)c1c(Cl)cccc1Cl.N#C/C(=C\c1c[nH]c2ncc(-c3cnn(C4CCNCC4)c3)cc12)c1c(Cl)cccc1Cl,1
1061,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase (ALK) expressed in Sf-21 insect cells upon incubation in 20 mM HEPES, pH 7.2 for 15 minutes at 37 degree C using 10 ug/mL PLC-gamma/GST as substrate in presence of 1 uM ATP was determined in a ELISA assay",human,IC50,nM,=,7.0,"Article; Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S.; Angeles, Thelma S.; Huang, Zeqi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6328 - 6341;",CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1,1
1059,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase (ALK) expressed in Sf-21 insect cells upon incubation in 20 mM HEPES, pH 7.2 for 15 minutes at 37 degree C using 10 ug/mL PLC-gamma/GST as substrate in presence of 1 uM ATP was determined in a ELISA assay",human,IC50,nM,=,7.0,"Article; Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S.; Angeles, Thelma S.; Huang, Zeqi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6328 - 6341;",COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,1
174,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,7.7,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCC(C)n1c2cc(N3CCN(C)CC3)c(OC)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
2007,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human ALK upon incubation using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP in 8 mM MOPS buffer, pH 7.0 for 40 mins at RT",NaN,IC50,nM,=,8.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2014/89324; (2014); A1;,CC1NCCc2cc(-c3cnc(N)c(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c3)ccc21,1
2009,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human ALK upon incubation using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP in 8 mM MOPS buffer, pH 7.0 for 40 mins at RT",NaN,IC50,nM,=,8.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2014/89324; (2014); A1;,C[C@@H](Oc1cc(-c2ccc3c(c2)CNC3)cnc1N)c1c(Cl)ccc(F)c1Cl,1
90,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,8.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,1
131,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,8.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",CC(C)S(=O)(=O)c1nn(C)cc1Nc1nc(Nc2cc(C#N)c(C3CCN(C)CC3)cc2OC2CC2)ncc1Cl,1
226,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,8.4,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCC3)c2c(F)c1N1CCC(N2CCOCC2)CC1,1
2006,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human ALK upon incubation using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP in 8 mM MOPS buffer, pH 7.0 for 40 mins at RT",NaN,IC50,nM,=,9.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2014/89324; (2014); A1;,C[C@@H](Oc1cc(-c2cc(F)c3c(c2)CCNC3)cnc1N)c1c(Cl)ccc(F)c1Cl,1
105,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,9.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCN(S(C)(=O)=O)CC1,1
53,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (dissolved in DMSO) against human ANAPLASTIC LYMPHOMA KINASE expressed in baculovirus upon incubation in 20 mM HEPES buffer, pH 7.2 using 10 ug/ml GST-PLC-GAMMA as subatrate in presence of 1 uM ATP at 37 degree C for 15 minutes by TIME RESOLVED FLUORESCENCE (TRF) ASSAY",human,IC50,nM,=,9.0,"Article; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 10; (2012); p. 4580 - 4593;",COCCNC1CCc2ccc(Nc3ncc(Cl)c(N[C@H]4[C@@H](C(N)=O)[C@@H]5C=C[C@H]4C5)n3)c(OC)c2CC1,1
1062,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase (ALK) expressed in Sf-21 insect cells upon incubation in 20 mM HEPES, pH 7.2 for 15 minutes at 37 degree C using 10 ug/mL PLC-gamma/GST as substrate in presence of 1 uM ATP was determined in a ELISA assay",human,IC50,nM,=,9.0,"Article; Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S.; Angeles, Thelma S.; Huang, Zeqi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6328 - 6341;",COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,1
1058,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase (ALK) expressed in Sf-21 insect cells upon incubation in 20 mM HEPES, pH 7.2 for 15 minutes at 37 degree C using 10 ug/mL PLC-gamma/GST as substrate in presence of 1 uM ATP was determined in a ELISA assay",human,IC50,nM,=,9.0,"Article; Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S.; Angeles, Thelma S.; Huang, Zeqi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6328 - 6341;",COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,1
101,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,10.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCN(C2COC2)CC1,1
24,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound against survival of human Karpas-299 cell line expressing NPM-ALK fusion protein upon incubation for 72 h at 37 degree C,NaN,IC50,µM,=,0.01,Patent; SYNTA PHARMACEUTICALS CORP.; US8034834; (2011); B2;,CC(C)c1cc(-c2nnc(O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,1
207,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound (dissolved in DMSO) against recombinant human GST-ANAPLASTIC LYMPHOMA KINASE expressed in Sf-21 insect cells in presence of 1 uM ATP upon incubation in 20 mM HEPES, pH 7.2 at 35 degree C for 15 min by ELISA",human,IC50,nM,=,10.0,Article; Antonia F. Stepan; Vincent Mascitti; Kevin Beaumont; Amit S. Kalgutkar; MedChemComm; vol. 4; 4; (2013); p. 631 - 652;,COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,1
117,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,10.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC(CF)CF)cc1C1CCN(C)CC1,1
113,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,10.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OCC2CC2)cc1C1CCNCC1,1
2150,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human recombinant Anaplastic lymphoma kinase (20 nM) upon incubation in 50 mM HEPES buffer, pH 7.5 in the presence of ATP (80 uM) and 33P-gamma-ATP (1 nM)",human,IC50,µM,=,0.01,Patent; NERVIANO MEDICAL SCIENCES S.R.L.; WO2010/69966; (2010); A1;,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4cc(OCc5cc(F)cc(F)c5)ccc34)c(NCCF)c2)CC1,1
2008,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human ALK upon incubation using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP in 8 mM MOPS buffer, pH 7.0 for 40 mins at RT",NaN,IC50,nM,=,11.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2014/89324; (2014); A1;,C[C@@H](Oc1cc(-c2cnc3c(c2)CCCN3)cnc1N)c1c(Cl)ccc(F)c1Cl,1
123,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,12.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(C(C)C)cc1C1CCN(C)CC1,1
171,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,12.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCC3)c2cc1N1CCN(C)CC1,1
1068,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Mutated:Substitution,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against mutant (L1196M) human ALK kinase in presence of 30 uM ATP upon incubation in 50 mM HEPES, pH 7.5 for 45 min at 25 degree C",NaN,IC50,µM,=,0.013,Patent; HANSOH PHARMACEUTICAL GROUP CO LTD; WO2015/81813; (2015); A1;,Cc1cc(Nc2ncc(OC(F)F)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,1
1078,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human ALK kinase in presence of 30 uM ATP upon incubation in 50 mM HEPES, pH 7.5 for 45 min at 25 degree C",NaN,IC50,µM,=,0.0135,Patent; HANSOH PHARMACEUTICAL GROUP CO LTD; WO2015/81813; (2015); A1;,Cc1cc(Nc2ncc(Cl)c(Nc3ccsc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,1
1072,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human ALK kinase in presence of 30 uM ATP upon incubation in 50 mM HEPES, pH 7.5 for 45 min at 25 degree C",NaN,IC50,µM,=,0.0137,Patent; HANSOH PHARMACEUTICAL GROUP CO LTD; WO2015/81813; (2015); A1;,Cc1cc(Nc2ncc(Cl)c(Nc3cccnc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,1
2040,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,15.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,C[C@@H](Oc1cc(-c2ccc([C@H]3CO[C@H]4[C@@H]3OC[C@H]4O)nc2)cnc1N)c1cc(Cl)ccc1Cl,1
115,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,15.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OCC2CC2)cc1C1CCN(C)CC1,1
1063,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase (ALK) expressed in Sf-21 insect cells upon incubation in 20 mM HEPES, pH 7.2 for 15 minutes at 37 degree C using 10 ug/mL PLC-gamma/GST as substrate in presence of 1 uM ATP was determined in a ELISA assay",human,IC50,nM,=,15.0,"Article; Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S.; Angeles, Thelma S.; Huang, Zeqi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6328 - 6341;",COc1cc(N2CCN(C[C@@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,1
61,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (dissolved in DMSO) against human ANAPLASTIC LYMPHOMA KINASE expressed in baculovirus upon incubation in 20 mM HEPES buffer, pH 7.2 using 10 ug/ml GST-PLC-GAMMA as subatrate in presence of 1 uM ATP at 37 degree C for 15 minutes by TIME RESOLVED FLUORESCENCE (TRF) ASSAY",human,IC50,nM,=,15.0,"Article; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew A.; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Haltiwanger, R. Curtis; Wells-Knecht, Kevin; Ott, Gregory R.; Ghose, Arup K.; Ator, Mark A.; Ruggeri, Bruce; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 10; (2012); p. 4580 - 4593;",COc1cc2c(cc1Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)CCC(N1CCN(C)CC1)CC2,1
251,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,15.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCCC3)c2cc1N1CCN(C)CC1,1
1074,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human ALK kinase in presence of 30 uM ATP upon incubation in 50 mM HEPES, pH 7.5 for 45 min at 25 degree C",NaN,IC50,µM,=,0.0163,Patent; HANSOH PHARMACEUTICAL GROUP CO LTD; WO2015/81813; (2015); A1;,CC(=O)N1CCC(c2cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4cccnc4S(=O)(=O)C(C)C)n3)cc2C)CC1,1
178,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,16.4,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCCn1c2cc(N3CCN(C)CC3)c(OC)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
247,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,16.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CC3)c2cc1N1CCN(C)CC1,1
246,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,17.8,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCC(N2CCOCC2)CC1,1
2023,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,18.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(N3CCNCC3)nc2)cnc1N)c1c(F)ccc(F)c1Cl,1
1859,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against N-terminal GST- tagged recombinant human Anaplastic lymphoma kinase expressed in insect cells using 250 uM KKKSPGEYVNIEFG as substrate and in presence of 10 mM [GAMMA-33P]ATP upon incubation in 8 mM MOPS buffer, pH 7.0 for 40 minutes at RT",NaN,IC50,µM,=,0.019,Patent; ASTRAZENECA PLC; WO2012/17239; (2012); A2;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(C)c(-c2c[nH]c3ccccc23)n1,1
2028,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,19.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CNCCC3O)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,1
2149,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human recombinant Anaplastic lymphoma kinase (20 nM) upon incubation in 50 mM HEPES buffer, pH 7.5 in the presence of ATP (80 uM) and 33P-gamma-ATP (1 nM)",human,IC50,µM,=,0.02,Patent; NERVIANO MEDICAL SCIENCES S.R.L.; WO2010/69966; (2010); A1;,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4cc(OCc5cc(F)cc(F)c5)ccc34)c(NC3CCOCC3)c2)CC1,1
139,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,20.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,C=C(C)c1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
2145,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,22.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",COc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl,1
121,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,22.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(C(F)(F)F)cc1C1CCN(C)CC1,1
235,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,22.9,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)Oc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1CCC(N2CCOCC2)CC1,1
164,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,23.6,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)n1c2cc(N3CCN(C)CC3)ccc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
177,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,24.7,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCn1c2cc(N3CCN(C)CC3)c(OC)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
211,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,24.7,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCOc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C3CCCC3)c2cc1N1CCN(C)CC1,1
103,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human wild-type ALK kinase in presence of 20 uM ATP upon incubation in 50 mM HEPES, pH 7.0 for 30 min using 1 uM TK-biotin substrate by HTRF kinease TK assay",NaN,IC50,nM,=,26.0,"Article; Zhang, Peilong; Dong, Jiaqiang; Zhong, Boyu; Zhang, Deyi; Jin, Can; Meng, Xuejing; Sun, Desheng; Xu, Xiangyuan; Zhou, Yong; Liang, Zhi; Ji, Minghua; Li, Hailong; Xu, Tao; Song, Guowei; Zhang, Ling; Chen, Gang; Yuan, Hongbin; Shih, Joe; Zhang, Ruihao; Hou, Guojun; Jin, Ying; Yang, Qiong; Bioorganic and Medicinal Chemistry Letters; vol. 25; 17; (2015); p. 3738 - 3743;",Cc1cc(Nc2ncc(Cl)c(Nc3cn(C)nc3S(=O)(=O)C(C)C)n2)c(OC2CC2)cc1C1CCN(C(=O)C(C)C)CC1,1
2024,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,27.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CNCCC3O)nc2)cnc1N)c1c(F)ccc(F)c1Cl,1
1950,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound (dissolved in DMSO) against recombinant human GST-ANAPLASTIC LYMPHOMA KINASE expressed in Sf-21 insect cells in presence of 1 uM ATP upon incubation in 20 mM HEPES, pH 7.2 at 35 degree C for 15 min by ELISA",human,IC50,nM,=,28.0,Article; Antonia F. Stepan; Vincent Mascitti; Kevin Beaumont; Amit S. Kalgutkar; MedChemComm; vol. 4; 4; (2013); p. 631 - 652;,COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,1
2020,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,28.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(N3CCNCC3)nc2)cnc1N)c1cc(Cl)ccc1Cl,1
279,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,28.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(CC(C)(C)C)c2cc1N1CCN(C)CC1,1
2021,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,29.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CO[C@@H]4[C@H](O)CO[C@H]34)nc2)cnc1N)c1cc(Cl)ccc1Cl,1
248,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,29.7,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CCC(CC)n1c2cc(N3CCN(C)CC3)c(OC)cc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
2042,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,31.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,C[C@@H](Oc1cc(-c2ccc([C@H]3CO[C@H]4[C@@H]3OC[C@H]4O)nc2)cnc1N)c1cc(F)ccc1F,1
2293,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against HUMAN ALK upon incubation in 8 mM MOPS, pH 7 for 40 mins at RT in presence of 10 uM [GAMMA-33P]ATP using 250 uM KKKSPGEYVNIEFG as substrate",NaN,IC50,nM,=,32.0,Patent; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; CALITOR SCIENCES LLC; WO2014/193647; (2014); A2;,Fc1ccc(Cl)c(/C=C/c2n[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)c1Cl.Fc1ccc(Cl)c(/C=C\c2n[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)c1Cl,1
2022,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,32.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CO[C@@H]4[C@H](O)CO[C@H]34)nc2)cnc1N)c1c(F)ccc(F)c1Cl,1
2229,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,32.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(cc(-c3ccnc(N4CCNCC4)c3)c1)N2.O=C(O)C(F)(F)F,1
2037,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,33.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CNCCC3O)nc2)cnc1N)c1c(Cl)cccc1Cl,1
163,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,33.1,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)n1c2cc(N3CCC(N4CCOCC4)CC3)ccc2c(=O)c2c3ccc(C#N)cc3[nH]c21,1
6,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,34.5,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1
2011,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (Disssolved in DMSO) against human recombinant wild type ALK upon incubation in presence of 30 uM ATP in 50 mM HEPES, pH 7.0 for 90 mins at RT was determined by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) FRET ASSAY",NaN,IC50,nM,=,34.8,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; WO2015/50989; (2015); A2;,C[C@@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)N(C)C(=O)COc2ccc(F)cc21,1
431,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,35.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",CNC(=O)c1ccc2cc1Nc1nc(ncc1Cl)Nc1ccc(N3CCN(C)CC3)c(c1)CC2,1
2038,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,39.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CNC[C@H](O)C3)nc2)cnc1N)c1c(Cl)cccc1Cl,1
2035,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,45.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3(O)CCOCC3)nc2)cnc1N)c1c(Cl)cccc1Cl,1
3144,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C[C@H]1CN(C(=O)[C@H]2CC[C@@H](n3/c(=N/C(=O)c4ccccc4)[nH]c4cnc(OCCN5CCCCC5)cc43)CC2)CCN1,1
3104,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1cc(F)cc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)c1,1
3102,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)c1,1
3166,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCCCC3)cc2n1C12CC3CC(CC(C3)C1)C2)c1ccccc1,1
3105,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)CNC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCOCC4)cc32)CC1,1
3153,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@H](C(=O)NC)CC2)c1,1
3145,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@]1(O)CC[C@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3151,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(=O)N[C@H]1CC[C@H](n2/c(=N/C(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,1
3149,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc4ccsc4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3147,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@H](C(N)=O)CC2)c1,1
3146,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3cncs3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3168,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)C(=O)N[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,1
3107,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]/c(=N\C(=O)c4ccc(F)cc4)n([C@H]4CC[C@H](C(N)=O)CC4)c3c2)CC1,1
3092,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,NC(=O)[C@]1(c2cccc(Br)c2)C[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,1
3080,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)CCNC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCCCC4)cc32)CC1,1
3082,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1ccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)cc1,1
3084,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3cccc(OC(F)(F)F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3087,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)N3CCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3089,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.05,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCOCC3)cc2n1[C@H]1CC[C@@H](C(=O)NO)CC1)c1ccc(F)cc1,1
3093,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)Nc2nccs2)CC1)c1ccc(F)cc1,1
3099,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)c(C(F)(F)F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3095,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3F)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
2029,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,50.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CCNCC3O)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,1
3097,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.05,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccnnc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
140,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,51.0,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,CC(C)c1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2cc1N1CCN(C)CC1,1
2018,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (Disssolved in DMSO) against human recombinant wild type ALK upon incubation in presence of 30 uM ATP in 50 mM HEPES, pH 7.0 for 90 mins at RT was determined by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) FRET ASSAY",NaN,IC50,nM,=,55.9,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; WO2015/50989; (2015); A2;,C[C@@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)NC(=O)COc2ccc(F)cc21,1
747,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound (dissolved in DMSO) against recombinant human GST-ANAPLASTIC LYMPHOMA KINASE expressed in Sf-21 insect cells in presence of 1 uM ATP upon incubation in 20 mM HEPES, pH 7.2 at 35 degree C for 15 min by ELISA",human,IC50,nM,=,56.0,Article; Antonia F. Stepan; Vincent Mascitti; Kevin Beaumont; Amit S. Kalgutkar; MedChemComm; vol. 4; 4; (2013); p. 631 - 652;,COc1cc(N2CCN(C[C@H](C)O)CC2)c(F)cc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1,1
1860,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5% DMSO) against human ALK upon incubation in presence of 1 uM ATP using 20 mM Hepes buffer , pH 7.2 for 15 min at 37 degree C",human,IC50,nM,=,56.0,"Article; Mesaros, Eugen F.; Thieu, Tho V.; Wells, Gregory J.; Zificsak, Craig A.; Wagner, Jason C.; Breslin, Henry J.; Tripathy, Rabindranath; Diebold, James L.; McHugh, Robert J.; Wohler, Ashley T.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Huang, Zeqi; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin J.; Aimone, Lisa D.; Cheng, Mangeng; Ator, Mark A.; Ott, Gregory R.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 115 - 125;",COc1c(Nc2ncc3ccc(-c4ccccc4N(C)S(C)(=O)=O)n3n2)ccc(N2CCN(C[C@H](C)O)CC2)c1F,1
2034,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,57.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CO[C@@H]4[C@H](O)CO[C@H]34)nc2)cnc1N)c1c(Cl)cccc1Cl,1
2148,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound aganist N-terminal GST-tagged recombinant human ALK (0.4 nM) expressed in insect cells using 1.5 uM SRCtide substrate, 5 mM ATP upon incubation in 50 mM HEPES, pH 7.3 for 90 min at RT",human,IC50,µM,=,0.06,Patent; ASTRAZENECA PLC; WO2009/16410; (2009); A3;,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)nc(N3CCCC(N(C)C(=O)OC(C)(C)C)C3)n2)n[nH]1,1
2033,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,61.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CO[C@@H]4[C@H](O)CO[C@H]34)nc2)cnc1N)c1cc(F)ccc1F,1
1953,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound against survival of human Karpas-299 cell line expressing NPM-ALK fusion protein upon incubation for 72 h at 37 degree C,NaN,IC50,µM,=,0.062,Patent; SYNTA PHARMACEUTICALS CORP.; US8034834; (2011); B2;,CO[C@H]1/C=C\C=C(C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,1
1954,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity of the compound against survival of human Karpas 299 cell line expressing NPM-ALK fusion protein upon incubation at 37 degree C for 72 h,NaN,IC50,µM,=,0.062,Patent; SYNTA PHARMACEUTICALS CORP.; US2008/4266; (2008); A1;,COC1C=C/C=C(\C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)CC(OC)[C@H](O)[C@@H](C)/C=C(\C)C1OC(N)=O)C2=O,1
2025,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,65.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CNC[C@H](O)C3)nc2)cnc1N)c1c(F)ccc(F)c1Cl,1
2026,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,66.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CCNCC3)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,1
2144,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,67.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4)n3)cc2)CC1,1
2036,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,69.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3(O)CCNCC3)nc2)cnc1N)c1c(Cl)cccc1Cl,1
1847,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,70.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,N#Cc1cccc(S(=O)(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)c1.O=C(O)C(F)(F)F,1
1910,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,76.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1ccccc1C(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,1
1827,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,80.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(C)S(=O)(=O)c1ccc2cc1Nc1nc(ncc1Cl)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,1
1916,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,80.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccc(F)cc1.O=C(O)C(F)(F)F,1
2031,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,83.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3(O)COCC3O)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,1
2220,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,86.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccncc1.O=C(O)C(F)(F)F,1
2237,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,91.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,NC(=O)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,1
1861,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5% DMSO) against human ALK upon incubation in presence of 1 uM ATP using 20 mM Hepes buffer , pH 7.2 for 15 min at 37 degree C",human,IC50,nM,=,91.0,"Article; Mesaros, Eugen F.; Thieu, Tho V.; Wells, Gregory J.; Zificsak, Craig A.; Wagner, Jason C.; Breslin, Henry J.; Tripathy, Rabindranath; Diebold, James L.; McHugh, Robert J.; Wohler, Ashley T.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Huang, Zeqi; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin J.; Aimone, Lisa D.; Cheng, Mangeng; Ator, Mark A.; Ott, Gregory R.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 115 - 125;",C[C@H](O)CN1CCN(c2cc(F)c(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2F)CC1,1
427,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,92.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",CN1CCN(c2ccc3cc2CCc2cccc(c2)Nc2nc(ncc2Cl)N3)CC1,1
1849,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,95.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(=O)Nc1ccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F,1
1907,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,96.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccccc1.O=C(O)C(F)(F)F,1
2041,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,98.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,C[C@@H](Oc1cc(-c2ccc([C@H]3CO[C@H]4[C@@H]3OC[C@H]4O)nc2)cnc1N)c1c(F)ccc(F)c1Cl,1
3139,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(C)OC(=O)N1CCC(n2/c(=N/C(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3138,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNCC(=O)N1CCC(n2/c(=N/C(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3083,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1cc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)ccc1F,1
3118,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,Cc1n[nH]c([C@H]2CC[C@@H](n3/c(=N/C(=O)c4cccc(F)c4)[nH]c4ccc(CO)cc43)CC2)n1,1
3085,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(/N=c1\[nH]c2cnc(OCCN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)N2CCNCC2)CC1)c1ccc(F)cc1,1
3086,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)N3CCOCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3088,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CN1CCN(C(=O)[C@H]2CC[C@@H](n3/c(=N/C(=O)c4ccc(F)cc4)[nH]c4ccc(CN5CCOCC5)cc43)CC2)CC1,1
3116,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,1
3156,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]/c(=N\C(=O)c2cccc(F)c2)n3[C@H]2CC[C@@H](C(=O)N3C[C@@H]4C[C@H]3CN4)CC2)CC1,1
3110,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCCCC4)cc32)CC1,1
3081,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)c1,1
3155,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3cccc(C(F)(F)F)c3)[nH]c3ccc(CO)cc32)CC1,1
3141,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C=CCNS(=O)(=O)c1cc(C(=O)Nc2nc3ccc(CO)cc3n2[C@H]2CC[C@@H](C(=O)OC)CC2)ccc1F,1
3172,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNC(=O)[C@]1(O)CC[C@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3068,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(Nc1nc2ccc(CO)cc2n1C12CC3CC(CC(C3)C1)C2)c1ccccc1,1
3070,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNS(=O)(=O)N1CCC(n2/c(=N/C(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3071,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)S(=O)(=O)N1CCC(n2/c(=N/C(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3073,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CCS(=O)(=O)N1CCC(n2/c(=N/C(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3075,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COC(=O)Nc1nc2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)NC(C)C)CC1,1
3170,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,Cl.O=C(Nc1nc2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)O)CC1)c1ccc(F)cc1,1
3143,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COCCCNS(=O)(=O)c1cc(C(=O)Nc2nc3ccc(CO)cc3n2[C@H]2CC[C@@H](C(=O)OC)CC2)ccc1F,1
3077,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C=CCNS(=O)(=O)c1cc(C(=O)Nc2nc3ccc(CN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)O)CC2)ccc1F,1
3079,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccccc3)[nH]c3cnccc32)CC1,1
1839,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,100.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccc(Cl)c1,1
3091,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,N#C[C@]1(c2cccc(Br)c2)C[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,1
3090,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]/c(=N\C(=O)c4cccc(F)c4)n([C@H]4CC[C@H](C(N)=O)CC4)c3c2)CC1,1
3136,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]/c(=N\C(=O)c4ccc(F)cc4)n([C@H]4CC[C@]5(CC4)NC(=O)NC5=O)c3c2)CC1,1
3114,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1C(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3132,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCOCC3)cc2n1[C@H]1CC[C@@H](C(=O)N2CCOCC2)CC1)c1ccc(F)cc1,1
3126,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(S(C)(=O)=O)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3127,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(C(N)=O)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3119,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]/c(=N\C(=O)c2cccc(F)c2)n3[C@H]2CC[C@@H](C(=O)N3CC(O)C3)CC2)CC1,1
3167,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(Nc1nc2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)O)CC1)c1ccc(F)cc1,1
3130,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)NC3CCCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3133,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]/c(=N\C(=O)c4ccc(F)cc4)n([C@H]4CC[C@@H](C(=O)O)CC4)c3c2)CC1,1
3124,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc4cc[nH]c4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3164,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,N#C[C@]1(c2ccccn2)C[C@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,1
3163,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNC(=O)[C@H]1CC[C@H](n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3161,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)C(=O)N[C@H]1CC[C@@H](n2/c(=N/C(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,1
3159,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@H](C(=O)NC(C)C)CC2)c1,1
3173,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,N#C[C@]1(c2ccccn2)C[C@H](n2c(NC(=O)c3ccc(F)cc3)nc3cnc(OCCN4CCCCC4)cc32)C1,1
3122,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against wild type human Anaplastic lymphoma kinase expressed in SF9 cells in presence of 40 uM ATP using 1 uM Biotin-Ahx-EQEDEPEGIYGVLF-OH as substrate upon incubation in 20 mM HEPES, pH 7.5 at RT for 90 minutes by TR FRET assay",NaN,IC50,µM,>=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2/c(=N/C(=O)c3ccc(C(F)(F)F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,1
3111,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against Human wild-type Anaplastic lymphoma kinase (2 nM) expressed in SF9 cells using 1 uM BIOTIN-AHX-EQEDEPEGIYGVLF-OH as substrate in presence of 40 uM ATP upon incubation at RT for 90 min in 20 mM HEPES, pH 7.5 by Time resolved fluorescence energy transfer (TR-FRET) assay",human,IC50,µM,>=,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](CO)CC1)c1ccc(F)cc1,1
2231,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,104.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(cc(-c3cnc(N4CCNCC4)nc3)c1)N2.O=C(O)C(F)(F)F,0
2232,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,108.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(cc(-c3ccc(N4CCNCC4)nc3)c1)N2.O=C(O)C(F)(F)F,0
2227,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,110.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(cc(-c3ccncc3)c1)N2.O=C(O)C(F)(F)F,0
2030,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,116.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CNC[C@H](O)C3)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,0
1815,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,130.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,COc1ccc2cc1Nc1nc(ncc1Cl)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,0
2247,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,130.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)c1ccncc1.O=C(O)C(F)(F)F,0
1938,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,130.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccs1,0
2032,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,131.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3(O)CCCOC3)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,0
2027,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,132.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,CC(Oc1cc(-c2ccc(C3CO[C@@H]4[C@H](O)CO[C@H]34)nc2)cnc1N)c1cc(Cl)ccc1C(F)(F)F,0
2228,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,138.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(cc(-c3cccnc3)c1)N2.O=C(O)C(F)(F)F,0
1823,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,140.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccccc1Cl,0
1178,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days,human,IC50,µM,=,0.15,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)N(C)C)n2)cc(OC)c1OC,0
1927,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,150.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,N#Cc1ccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F,0
2233,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,150.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(=O)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,0
1934,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,150.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CS(=O)(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1940,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,150.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1cccc(S(=O)(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)c1.O=C(O)C(F)(F)F,0
2230,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,157.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1n[nH]c(C)c1-c1cc2cc(c1)Nc1ncc(Cl)c(n1)Nc1cccc(c1)OCC2.O=C(O)C(F)(F)F,0
1915,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,160.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccc(F)c1.O=C(O)C(F)(F)F,0
2248,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,160.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1nc(S(=O)(=O)Nc2cc3cc(c2)OCCSc2cccc(c2)Nc2nc(ncc2Cl)N3)cn1C.O=C(O)C(F)(F)F,0
1824,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,170.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccc(Cl)cc1,0
1942,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,180.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1ccc(S(=O)(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F,0
1914,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,180.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1ccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F,0
2238,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,182.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,NC(=O)N1CCN(c2ccc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)cn2)CC1.O=C(O)C(F)(F)F,0
1951,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound (dissolved in DMSO) against recombinant human GST-ANAPLASTIC LYMPHOMA KINASE expressed in Sf-21 insect cells in presence of 1 uM ATP upon incubation in 20 mM HEPES, pH 7.2 at 35 degree C for 15 min by ELISA",human,IC50,nM,=,187.0,Article; Antonia F. Stepan; Vincent Mascitti; Kevin Beaumont; Amit S. Kalgutkar; MedChemComm; vol. 4; 4; (2013); p. 631 - 652;,COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,0
1833,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,200.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)c1ccno1.O=C(O)C(F)(F)F,0
1911,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,210.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccccc1F.O=C(O)C(F)(F)F,0
1925,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,210.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccsc1.O=C(O)C(F)(F)F,0
1930,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,220.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,COc1ccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F,0
2234,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,225.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CS(=O)(=O)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,0
1917,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,230.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cn1cccc1C(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1836,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,238.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CS(=O)(=O)c1ccc(-c2cc3cc(c2)Nc2ncc(Cl)c(n2)Nc2cccc(c2)OCC3)cc1.O=C(O)C(F)(F)F,0
1933,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,240.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccccc1,0
2235,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,248.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(=O)N1CCN(c2ccc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)cn2)CC1.O=C(O)C(F)(F)F,0
425,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,259.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",COc1ccc2cc1Nc1nc(ncc1Cl)Nc1ccc(N3CCN(C)CC3)c(c1)/C=C\2,0
1060,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase (ALK) expressed in Sf-21 insect cells upon incubation in 20 mM HEPES, pH 7.2 for 15 minutes at 37 degree C using 10 ug/mL PLC-gamma/GST as substrate in presence of 1 uM ATP was determined in a ELISA assay",human,IC50,nM,=,260.0,"Article; Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S.; Angeles, Thelma S.; Huang, Zeqi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 54; 18; (2011); p. 6328 - 6341;",CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5NS(C)(=O)=O)n4n3)cc2)CC1,0
2218,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,260.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccnc1.O=C(O)C(F)(F)F,0
1237,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days,human,IC50,µM,=,0.27,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN(C)S(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCn3ccnc3)c2)n1,0
1855,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase using (0.5 uM) Biotin-KKKGPWLEEEEEAYGWLDF-amide as substrate and in presence of 90 uM ATP upon incubation in 50 mM Tris,pH 7.8 for 2 h at 25 degree C",NaN,IC50,nM,=,280.0,Patent; INCYTE CORP; WO2010/85597; (2010); A1;,Clc1cnc2nc1NCc1cc(Br)cc(c1)OCCCc1cccc(c1)N2,0
1943,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,280.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,N#Cc1ccc(S(=O)(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cc1.O=C(O)C(F)(F)F,0
2239,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,280.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(C)(C)NC(=O)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,0
426,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,283.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",Clc1cnc2nc1Nc1cccc(c1)CCc1cc(ccc1OCCN1CCCC1)N2,0
1928,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,290.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,N#Cc1cccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)c1.O=C(O)C(F)(F)F,0
1843,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,290.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccc(Cl)cc1,0
2221,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,300.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cnccn1.O=C(O)C(F)(F)F,0
2222,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,300.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cn1cncc1C(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
245,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,309.0,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C)c2cc1N1CCN(C)CC1,0
1825,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,310.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccc(Cl)c1,0
1929,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,310.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,COc1cccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)c1.O=C(O)C(F)(F)F,0
1810,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,327.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)SCCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1913,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,330.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1cccc(C(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)c1.O=C(O)C(F)(F)F,0
1280,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days,human,IC50,µM,=,0.33,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCCNS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cc(OC)c(OC)c(OC)c2)n1,0
2243,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,340.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(NCc1ccccc1)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,0
1841,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,340.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)c1ccccc1,0
1941,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,350.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1ccccc1S(=O)(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1819,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,350.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.Oc1ccc2cc1Nc1nc(ncc1Cl)Nc1cccc(c1)CC2,0
1808,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,351.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
2249,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,375.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCNc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1835,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,380.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)c1ccco1.O=C(O)C(F)(F)F,0
2241,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,390.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,COC(=O)c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
2143,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,390.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(NC1CCCC1)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,0
424,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"In vitro inhibitory concentration of the compound (dissolved in 2.5 % DMSO) against baculovirus expressed human Anaplastic lymphoma kinase upon incubation with 20 mM HEPES buffer, pH 7.2, for 1 hour at 37 degree C using 10 ug/mL recombinant PLC-gamma/GST substrate in presence of 1 uM ATP by Time resolved fluorescence (TRF) assay",human,IC50,nM,=,392.0,"Article; Breslin, Henry J.; Lane, Brandon M.; Ott, Gregory R.; Ghose, Arup K.; Angeles, Thelma S.; Albom, Mark S.; Cheng, Mangeng; Wan, Weihua; Haltiwanger, R. Curtis; Wells-Knecht, Kevin J.; Dorsey, Bruce D.; Journal of Medicinal Chemistry; vol. 55; 1; (2012); p. 449 - 464;",CN1CCN(c2ccc3cc2/C=C\c2cccc(c2)Nc2nc(ncc2Cl)N3)CC1,0
2253,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,400.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CCCNc1cccc(c1)N2.O=C(O)C(F)(F)F,0
2257,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,415.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)C=Cc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1947,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,420.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=C(c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)N1CCOCC1,0
1846,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,430.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1noc(C)c1S(=O)(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1832,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,430.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)c1ccccc1.O=C(O)C(F)(F)F,0
1912,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,430.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1noc(C)c1C(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
2236,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,442.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CS(=O)(=O)N1CCN(c2ccc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)cn2)CC1.O=C(O)C(F)(F)F,0
1949,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,450.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Cc1ccccc1)Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
1828,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,470.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1cccs1.O=C(O)C(F)(F)F,0
2242,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,480.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1)N1CCN(c2cc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)ccn2)CC1.O=C(O)C(F)(F)F,0
1814,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,480.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)SCCOc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1816,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,489.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(Br)cc(c1)N2.O=C(O)C(F)(F)F,0
1844,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,490.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1cc(C(=O)Nc2cc3cc(c2)OCCSc2cccc(c2)Nc2nc(ncc2Cl)N3)no1.O=C(O)C(F)(F)F,0
1831,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,497.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1cc(N2CCOCC2)c2cc1Nc1ncc(Cl)c(n1)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,0
2835,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC(c2ccccc2)c2ccccc2)cs1,0
2795,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2783,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2cccs2)co1,0
2786,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCc1ccc(NC(=O)NCc2nc(C(=O)NCc3cccc(OC)c3OC)cs2)cc1,0
2790,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC1CCC(NC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CC1,0
2791,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCOc1ccc(NC(=O)NCc2nc(C(=O)NCc3ccccc3OC)cs2)cc1,0
2793,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCCCC2)cs1,0
2794,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1)N[C@@H]1C[C@H]1c1ccccc1,0
2796,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(Cc1ccc2ccccc2c1)NCc1nc(C(=O)NCCc2ccccc2F)cs1,0
2779,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)(C)CC(C)(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2797,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccc2)cs1,0
2799,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CNC(=O)c2csc(CNC(=O)COc3ccc(C(C)C)cc3)n2)c1OC,0
2800,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCOc2ccccc2)cs1,0
2802,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@@H](CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2807,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)CCCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2808,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2780,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCC(CC)CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2775,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccn2)cs1,0
2810,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccsc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2764,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCc1ccc(NC(=O)NCc2nc(C(=O)NCCc3ccccc3F)cs2)cc1,0
2755,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(Cl)cc1)NCc1nc(C(=O)NCCc2ccccc2F)cs1,0
2756,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1cccc(Cl)c1)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2757,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2759,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@H](NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)C(C)(C)C,0
2760,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccs2)cs1,0
2761,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSc1ccc(NC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2765,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)(C)CCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2774,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1ccc(NC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2766,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)c1ccc(CC(=O)NCc2nc(C(=O)NCCc3ccccc3F)cs2)cc1,0
2767,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(Br)cc1)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2768,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCC2CC2)cs1,0
2769,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCSCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2772,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2773,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCc1ccc(OCC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2809,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(Cc1ccc2ccccc2c1)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2812,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2752,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCC(CC)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2851,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)C[C@@H](NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)C(N)=O,0
2842,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCc3ccccc32)cs1,0
2843,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2cccc(Cl)c2)co1,0
2845,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccc2Cl)cs1,0
2847,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccc2F)co1,0
2848,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCC2CCCCC2)cs1,0
2849,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1cc(Cl)ccc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2852,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2cccc(F)c2)co1,0
2840,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(CNC(=O)c1ccc([N+](=O)[O-])cc1)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2856,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(F)cc2)co1,0
2858,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccc(I)c2)cs1,0
2861,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCN2CCOCC2)cs1,0
2862,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CN(CCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2863,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c(OC)c1,0
2864,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cc(F)cc(F)c2)cs1,0
2841,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(NCCc1ccccc1F)c1csc(CNC(=O)c2cccnc2Oc2ccc(Cl)cc2)n1,0
3067,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,<,0.5,Patent; AMGEN INC; WO2011/143033; (2011); A1;,COc1cc(Nc2nccc(N3CCC[C@H](C(=O)NCc4ccc(C(C)(C)C)cc4)C3)n2)cc(OC)c1OC,0
2813,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2824,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccc(F)c2)cs1,0
2816,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(CCc1ccccc1)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2817,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSc1ccccc1CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2818,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2819,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCC(CC)CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2821,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C#CC(CC)(CC)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2823,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc([C@H](C)NC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2825,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)c2cccnc2Oc2ccc(Cl)cc2)n1,0
2833,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(NCCc1cccc(Cl)c1)c1csc(CNC(=O)c2cccnc2Oc2ccc(F)cc2)n1,0
2826,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc([C@H](C)NC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2827,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2829,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1cccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2830,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(F)cc2)cs1,0
2831,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2832,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccc2Cl)cs1,0
2753,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)Nc2ccc(C(C)C)cc2)n1,0
2751,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCC(C)CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2866,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)CCCCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2700,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,NC(=O)C(NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2694,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2695,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2696,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCOCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2697,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(Cl)cc2)cs1,0
2698,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2699,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(Cl)cc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2701,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(NCCc1cccc(Cl)c1)c1csc(CNC(=O)c2cccnc2Oc2ccc(Cl)cc2)n1,0
2692,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2702,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(Br)cc2)cs1,0
2703,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1cccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1C,0
2704,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cc(F)ccc2F)cs1,0
2705,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(F)cc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2706,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(Cl)cc2Cl)cs1,0
2707,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1C,0
2693,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccc(F)cc1,0
2691,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCSCc2ccco2)cs1,0
2750,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(NC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2682,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CNC(=O)c2csc(CNC(=O)Nc3ccc(C(C)C)cc3)n2)c1OC,0
2676,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2677,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(I)cc2)n1,0
2678,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)c1ccc(CC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2679,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)c1ccc(OCC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2680,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(I)cc1)NCc1nc(C(=O)NCCc2ccccc2F)cs1,0
2681,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)c1ccc(OCC(=O)NCc2nc(C(=O)NCCc3ccccc3F)cs2)cc1,0
2683,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)(C)c1ccc(OCC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2690,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCOCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2684,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccn2)cs1,0
2685,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCC(NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2686,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccncc2)cs1,0
2687,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2cccnc2)cs1,0
2688,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2689,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC1CCCCC1NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2708,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCC2=CCCCC2)cs1,0
2709,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c(C)c1,0
2710,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(Cl)c(Cl)c2)cs1,0
2736,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)C(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2729,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2cccc(C(F)(F)F)c2)cs1,0
2730,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCSCc2c(Cl)cccc2Cl)cs1,0
2731,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CCc3c([nH]c4ccccc34)C2)cs1,0
2732,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(Cl)c(C(F)(F)F)c2)cs1,0
2733,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CCN(c3c(Cl)cncc3Cl)CC2)cs1,0
2734,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCCC2)cs1,0
2739,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)Cc2ccc(C(C)C)cc2)n1,0
2711,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cc(Cl)cc(Cl)c2)cs1,0
2740,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)[C@H](C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2741,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(C/C=C/c1ccccc1)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2743,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(C(C)C)cc2)n1,0
2744,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCc1ccc(NC(=O)NCc2nc(C(=O)NCc3ccccc3OC)cs2)cc1,0
2745,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2749,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)CCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2728,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCN(Cc3ccccc3)CC2)cs1,0
2727,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1ccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1OC,0
2726,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2c[nH]c3ccccc23)cs1,0
2725,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccc2OC(F)(F)F)cs1,0
2724,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1OC,0
2723,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)c1csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n1)C2(C)C,0
2722,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,NC(=O)[C@@H](Cc1ccccc1)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2721,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(Cl)c(Cl)c2)cs1,0
2720,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N[C@H]2CCCc3ccccc32)cs1,0
2719,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1OC,0
2718,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1ccccc1CCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2717,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccc2C(F)(F)F)cs1,0
2716,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@H](NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)C1CCCCC1,0
2715,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(OCCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2714,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1ccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2713,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCCCCCC2)cs1,0
2712,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1cccc2ccccc12,0
2865,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(OC)c1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2879,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2c(F)cccc2F)cs1,0
2868,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CNC(=O)c2csc(CNC(=O)c3cccnc3Oc3ccc(Cl)cc3)n2)c1OC,0
2927,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccc(C(F)(F)F)c2F)cs1,0
2908,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@@H]1[C@@H](NC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)C[C@H]2C[C@@H]1C2(C)C,0
2911,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1cc(Cl)cc(Cl)c1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2914,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)Nc2ccc(C(=O)O)c(O)c2)cs1,0
2917,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2cccc(C(F)(F)F)c2)co1,0
2918,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CN(C)Cc1ccc(CSCCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)o1,0
2919,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccc2Oc2ccccc2)cs1,0
2922,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N[C@H]2CCC[C@@H]2OCc2ccccc2)cs1,0
2923,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N[C@@H]2CCC[C@H]2OCc2ccccc2)cs1,0
2926,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCC(CC)COCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2929,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cc(C(F)(F)F)ccc2Cl)cs1,0
2902,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,NC(=O)[C@H](Cc1ccccc1)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2930,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(F)c(C(F)(F)F)c2)cs1,0
2931,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2c(Cl)cccc2Oc2ccccc2)cs1,0
2932,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NC(Cc1ccccc1)c1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2870,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(NC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1cccc2ccccc12,0
3058,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2C[C@H]3CC[C@@H]2C3)cs1,0
3059,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)(C)OC(=O)NCCCCCNC(=O)c1ncsc1CNC(=O)COc1ccc(OC(F)(F)F)cc1,0
3066,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),Enzymology inhibition,NaN,NaN,IC50,µM,<,0.5,Patent; AMGEN INC; WO2011/143033; (2011); A1;,COc1cc(Nc2nccc(N3CCC[C@H](C(=O)NCc4cccc(-c5ccccc5)c4)C3)n2)cc(OC)c1OC,0
3060,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCCC(C)N(C)C(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
3061,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2903,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(OC)c(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2920,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1onc(-c2ccccc2)c1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2900,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N[C@@H]2CCCc3ccccc32)cs1,0
2887,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccc(F)c2F)cs1,0
2875,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc(OC)c1,0
2899,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C#CC1(NC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CCCCC1,0
2874,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(F)c(F)c2)cs1,0
2873,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCC2=CCCCC2)co1,0
2871,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(C)c(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2881,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCCc3ccccc32)cs1,0
2883,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1cccc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2884,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1C,0
2888,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(F)c(Cl)c2)cs1,0
2889,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(OC)c(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2891,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cc(CCNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc(OC)c1,0
2892,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc(OC)c1,0
2894,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCN(CCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1cccc(C)c1,0
2895,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccc(C(F)(F)F)c2)cs1,0
2896,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1OC,0
2897,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(Cl)cc2Cl)cs1,0
2898,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccc2OC(F)F)cs1,0
2878,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 50 to < 500 nM",human,IC50,nM,<,500.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1OC,0
2290,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity of the compound against survival of human Karpas 299 cell line expressing NPM-ALK fusion protein upon incubation at 37 degree C for 72 h,NaN,IC50,µM,=,0.506,Patent; SYNTA PHARMACEUTICALS CORP.; US2008/4266; (2008); A1;,C=CCNC1=C2C[C@@H](C)CC(OC)[C@H](O)[C@@H](C)/C=C(\C)C(OC(N)=O)C(OC)C=C/C=C(\C)C(=O)NC(=CC1=O)C2=O,0
1809,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,509.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CCOc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1812,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,523.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1ccc2cc1Nc1ncc(Cl)c(n1)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,0
1826,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,525.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCc1cc(cc(-c3ccccc3)c1)N2.O=C(O)C(F)(F)F,0
2245,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,560.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(NC1CCCC1)N1CCN(c2ccc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)cn2)CC1.O=C(O)C(F)(F)F,0
1799,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,562.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.Clc1cnc2nc1Nc1cccc(c1)CCSc1cccc(c1)N2,0
2256,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,570.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)SCCNc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1842,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,580.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccccc1Cl,0
1805,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,598.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CSCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1926,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,600.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)C1CCCCC1.O=C(O)C(F)(F)F,0
2224,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,600.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cn1cnc(S(=O)(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)c1.O=C(O)C(F)(F)F,0
1834,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,610.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)c1cccs1.O=C(O)C(F)(F)F,0
2244,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,610.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(C)(C)NC(=O)N1CCN(c2ccc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)cn2)CC1.O=C(O)C(F)(F)F,0
2216,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,610.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2,0
1800,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,620.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)SCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1803,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,657.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
243,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,661.0,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C)c2cc1N1CCC(N2CCOCC2)CC1,0
1924,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,680.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CCC(C)C(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1923,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,700.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccoc1.O=C(O)C(F)(F)F,0
1858,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase using (0.5 uM) Biotin-KKKGPWLEEEEEAYGWLDF-amide as substrate and in presence of 90 uM ATP upon incubation in 50 mM Tris,pH 7.8 for 2 h at 25 degree C",NaN,IC50,nM,=,706.0,Patent; INCYTE CORP; WO2010/85597; (2010); A1;,Clc1cnc2nc1NCc1cccc(c1)OCCCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1918,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,720.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccno1.O=C(O)C(F)(F)F,0
1921,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,720.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CCCC(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1845,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,730.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1Cl)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
2240,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,730.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1)N1CCN(c2ccc(-c3cc4cc(c3)Nc3ncc(Cl)c(n3)Nc3cccc(c3)OCC4)cn2)CC1.O=C(O)C(F)(F)F,0
1821,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,732.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1(=O)CCOc2cccc(c2)Nc2ncc(Cl)c(n2)Nc2cccc1c2,0
1935,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,740.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CCS(=O)(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1848,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,770.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(NCc1ccccc1)Nc1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
2250,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,772.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)NCCOc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1801,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,774.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CSc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1813,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,774.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1(=O)Cc2cccc(c2)Nc2nc(ncc2Cl)Nc2cccc1c2,0
1931,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,780.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1820,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,781.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.OCc1cc2cc(c1)Nc1nc(ncc1Cl)Nc1cccc(c1)CC2,0
2214,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,786.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1cnc2nc1Nc1cccc(c1)C=Cc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1804,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,791.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)OCCOc1cccc(c1)N2.O=C(O)C(F)(F)F,0
2254,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,791.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CCNc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1909,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,820.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccco1.O=C(O)C(F)(F)F,0
2039,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human ALK using 250 uM KKKSPGEYVNIEFG as substrate in presence of 10 uM [GAMMA-33P]ATP upon incubation in 8 mM MOPS, pH 7.0 at RT for 40 mins",NaN,IC50,nM,=,837.0,Patent; CALITOR SCIENCES LLC; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO LTD; WO2015/34729; (2015); A1;,C[C@H](Oc1cc(-c2ccc([C@H]3CO[C@H]4[C@@H]3OC[C@H]4O)nc2)cnc1N)c1cc(Cl)ccc1Cl,0
1905,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,880.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)C1CC1.O=C(O)C(F)(F)F,0
2147,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound aganist N-terminal GST-tagged recombinant human ALK (0.4 nM) expressed in insect cells using 1.5 uM SRCtide substrate, 5 mM ATP upon incubation in 50 mM HEPES, pH 7.3 for 90 min at RT",human,IC50,µM,=,0.903,Patent; ASTRAZENECA PLC; WO2009/16410; (2009); A3;,COCC(Nc1nc(Nc2cc(C)[nH]n2)nc(N2CCC(OC)CC2)n1)c1ncc(F)cc1F,0
2223,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,910.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1nccs1.O=C(O)C(F)(F)F,0
1840,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,910.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(NCc1ccccc1)c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
1797,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,925.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CCCc1cccc(c1)N2,0
1932,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,930.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)NC1CCCC1.O=C(O)C(F)(F)F,0
1920,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,930.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(C)C(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1908,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,940.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Cc1ccccc1)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1919,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,970.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CCC(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1807,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,976.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Brc1cnc2nc1Nc1cccc(c1)CCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1806,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,984.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)COCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1936,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,990.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CCCS(=O)(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1670,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,CCc1cc(-c2nc3[nH]nc(C)c3c3cc(OC)c(OC)cc23)ccc1O,0
1664,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)c(F)c3)nc3[nH]nc(C)c3c2cc1OC,0
1665,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc(-c2nc3[nH]nc(C)c3c3cc(OC)c(OC)cc23)ccc1O,0
1667,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1c(Cl)cc2c(-c3ccc(O)cc3)nc3[nH]nc(C)c3c2c1F,0
1693,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(Cc4cccc(C)c4)c3c2cc1OC,0
1672,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COCc1n[nH]c2nc(-c3ccc(O)c(Cl)c3)c3cc(OC)c(OC)cc3c12,0
1673,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,CCOc1cc2c(cc1OC)c(-c1ccc(O)c(Cl)c1)nc1[nH]nc(C)c12,0
1675,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,Cc1n[nH]c2nc(-c3ccccc3F)c3c(F)cc4c(c3c12)OCCO4,0
1677,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(-c3cc(C)c(O)cc3C)nc3[nH]nc(C)c3c2cc1OC,0
1662,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(C(C)C)c3c2cc1OC,0
1660,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,CCc1n[nH]c2nc(-c3ccc(O)cc3)c3cc(OC)c(OC)cc3c12,0
1980,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"IInhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,Cc1n[nH]c2nc(-c3nnc(N)s3)c3c(F)cc(O)c(F)c3c12,0
1978,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,Cc1n[nH]c2nc(-c3ccc(N)s3)c3c(F)cc(O)c(F)c3c12,0
1972,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)c(Cl)c3)nc3[nH]nc(C(F)(F)F)c3c2cc1OC,0
1970,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)c(Cl)c3)nc3[nH]ncc3c2cc1OC,0
1968,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)cc3[nH]nc(C)c3c2c(F)c1OC,0
1651,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc(OC)c2c(-c3ccc(O)cc3)nc3[nH]ncc3c2c1,0
1653,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]ncc3c2cc1OC,0
1655,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,CCOc1cc2c(cc1OC)c(-c1ccc(O)cc1)nc1[nH]nc(C)c12,0
1657,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,CCOc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(C)c3c2cc1OC,0
1679,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,CCOc1cc(-c2nc3[nH]nc(C)c3c3cc(OC)c(OC)cc23)ccc1O,0
1681,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(C(F)(F)F)c3c2cc1OC,0
1710,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(CNCc4ccccc4)c3c2cc1OC,0
1708,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)c(Cl)c3)nc3[nH]nc(C)c3c2cc1OCC(F)(F)F,0
1706,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(CN4CCCC4=O)c3c2cc1OC,0
1960,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(C4CCN(C(=O)OC(C)(C)C)CC4)c3c2cc1OC,0
1961,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1ccc2c(-c3ccc(O)c(Br)c3)nc3[nH]nc(C)c3c2c1OCCN1CCOCC1,0
1702,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1ccc(Cc2n[nH]c3nc(-c4ccc(O)cc4)c4cc(OC)c(OC)cc4c23)cc1,0
1700,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(Cc4ccccc4C)c3c2cc1OC,0
1964,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1ccc2c(-c3ccc(O)c(Cl)c3)nc3[nH]nc(C)c3c2c1OCCN1CCOCC1,0
1696,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(Cc4ccc(C)cc4)c3c2cc1OC,0
1711,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(cc1OCCN1CCOCC1)c(-c1ccc(O)cc1)nc1[nH]nc(C)c12,0
1690,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(c(-c3ccc(O)c(Cl)c3)nc3[nH]nc(C)c32)c(Cl)c1OC,0
1966,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(cc1F)c(-c1ccc(O)cc1)nc1[nH]nc(C)c12,0
1685,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(-c3ccc(O)c(Cl)c3)nc3[nH]nc(C)c3c2cc1OCC(C)C,0
1687,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,Cc1n[nH]c2nc(-c3ccc4[nH]ccc4c3)c3c(F)cc(O)c(F)c3c12,0
1958,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(cc1OCC1CCNCC1)c(-c1ccc(O)cc1)nc1[nH]nc(C)c12,0
1955,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1cc2c(-c3ccc(O)cc3)nc3[nH]nc(Cc4ccccc4)c3c2cc1OC,0
1718,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COCCOc1cc2c(-c3ccc(O)c(Br)c3)nc3[nH]nc(C)c3c2cc1OCCOC,0
1716,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COCCOc1cc2c(-c3ccc(O)c(Cl)c3)nc3[nH]nc(C)c3c2cc1OCCOC,0
1039,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range-100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,Cc1n[nH]c2cc(-c3ccc(O)cc3)c3ccccc3c12,0
1040,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 100-999 nM",NaN,IC50,nM,=,999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1ccc2c(-c3ccc(O)cc3)nc3[nH]nc(Cc4ccccc4)c3c2c1,0
423,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
693,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN5CCCC5)c4)c3n2)cc(OC)c1OC,0
686,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCCN(C)C)c4)c3n2)cc(OC)c1OC,0
689,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCCN)c4)c3n2)cc(OC)c1OC,0
2045,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3ccccc3)n2)ccc2c1OCCO2,0
695,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccs4)c3n2)cc(OC)c1OC,0
2003,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CN1CCN(CCOc2ccc(Nc3ncc4ccn(-c5ccccn5)c4n3)cc2)CC1,0
2000,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CC(C)NCCCNc1ccc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc1,0
685,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)CNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
2046,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)c1,0
2047,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1,0
2064,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCc4ccccc4)c3S(N)(=O)=O)n2)cc1OC,0
2063,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1C,0
2062,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)CCC4)n2)cc1OC,0
2061,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CC(=O)c1cccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)c1,0
2060,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1SC,0
2059,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCO4)n2)cc1N(C)C,0
2058,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=CCOc1cccc(Nc2ccnc(Nc3ccc(OC)c(N(C)C)c3)n2)c1S(N)(=O)=O,0
2057,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1F,0
2056,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1C,0
2055,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1OC,0
2054,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCOc1cccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)c1,0
2053,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC(F)F)c3S(N)(=O)=O)n2)cc1OC,0
2052,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCCOc1cccc(Nc2ccnc(Nc3ccc(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
2051,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)OCO5)n3)cc21,0
2050,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)c1,0
2049,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=CCOc1cccc(Nc2ccnc(Nc3ccc4cnn(C)c4c3)n2)c1S(N)(=O)=O,0
2048,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cc1cccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)c1,0
1997,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC(C(=O)O)C(C)(C)C)c4)c3n2)cc(OC)c1OC,0
2066,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1N(C)C,0
2950,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)CCNC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCCCC4)cc32)CC1,0
765,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl,0
2943,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(=O)C1CCC(n2/c(=N/C(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
2944,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)N3CCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2945,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]/c(=N\C(=O)c4ccc(F)cc4)n(C4CCC(C(=O)O)CC4)c3c2)CC1,0
2946,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(=O)NC1CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
2947,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)CNC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCOCC4)cc32)CC1,0
2948,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCCCC3)cc2n1C1CCC(C(=O)Nc2nccs2)CC1)c1ccc(F)cc1,0
2949,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COc1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)c1,0
2951,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)N3CCOCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2941,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NCC1CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCCCC4)cc32)CC1,0
2952,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCOCC3)cc2n1C1CCC(C(=O)N2CCOCC2)CC1)c1ccc(F)cc1,0
2954,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CN1CCN(C(=O)C2CCC(n3/c(=N/C(=O)c4ccc(F)cc4)[nH]c4ccc(CN5CCOCC5)cc43)CC2)CC1,0
2955,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc4ccsc4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2956,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(S(C)(=O)=O)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2957,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)NC3CCCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2958,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COc1cc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)ccc1F,0
2959,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COc1cc(F)cc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)c1,0
2960,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(C(N)=O)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2942,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3nccs3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2940,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCOCC3)cc2n1C1CCC(C(=O)NO)CC1)c1ccc(F)cc1,0
1987,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Concentration required to inhibit proliferation of murine BaF3 cells expressing human Anaplastic lymphoma kinase (NPM-ALK fusion protein) upon incubation for 2 days with compound dissolved in DMSO in the absence of IL-3; Range 0.01- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN3CCOCC3C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1994,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(n2)N(c2ccccn2)[C@@H](O)[C@@H]3O)cc(OC)c1OC,0
1993,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cccc(Nc2ncc3ccn(CCc4ccncc4)c3n2)c1,0
1990,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1,0
2938,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2ccc(CN3CCCCC3)cc2n1C1CCC(CO)CC1)c1ccc(F)cc1,0
1985,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Concentration required to inhibit autophosphorylation of human Anaplastic lymphoma kinase in KARPAS-299 lymphoma cells; Range 0.001- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC)ncc1Br,0
1982,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(Br)c(Nc3ccccc3S(=O)(=O)NCC=C3CC3)n2)cc(OC)c1OC,0
2933,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COC(=O)C1CCC(n2/c(=N/C(=O)c3ccccc3)[nH]c3cnccc32)CC1,0
2936,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COC(=O)C1CCC(n2/c(=N/C(=O)c3cccc(C(F)(F)F)c3)[nH]c3ccc(CO)cc32)CC1,0
2937,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,Cc1n[nH]c(C2CCC(n3/c(=N/C(=O)c4cccc(F)c4)[nH]c4ccc(CO)cc43)CC2)n1,0
2065,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(Cl)COc1cccc(Nc2ccnc(Nc3ccc(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
2067,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCCO4)n2)cc1OC,0
2962,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C=CCNS(=O)(=O)c1cc(C(=O)Nc2nc3ccc(CN4CCCCC4)cc3n2C2CCC(C(=O)O)CC2)ccc1F,0
2122,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CN1CCN(CCOc2cccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)OCCCO5)n3)c2)CC1,0
2130,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3-c3nnn[nH]3)n2)cc(OC)c1OC,0
2129,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CC(=O)Nc1cccc(Nc2nccc(Nc3ccccc3-c3nnn[nH]3)n2)c1,0
2127,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1OCCN1CCN(C)CC1,0
2126,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)CCC4)n2)cc1OCCN1CCOCC1,0
2125,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)CCC4)n2)cc1OCCN1CCCCC1,0
2124,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1OCCN1CCOCC1,0
2123,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCCCC(F)(F)C(F)(F)F)c3S(N)(=O)=O)n2)cc1N(C)C,0
2121,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCN4CCOCC4)c3)n2)ccc2c1OCCCO2,0
2132,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,c1cncc(CNc2cccc(Nc3nccc(Nc4ccccc4-c4nnn[nH]4)n3)c2)c1,0
2120,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCCCC(F)(F)C(F)(F)F)c3S(N)(=O)=O)n2)cc1OC,0
2119,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(F)(F)C(F)(F)O4)n2)ccc1OC,0
2118,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)ccc2c1CCC2,0
2117,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)ccc2c1OCCO2,0
2116,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCC4CCCCC4)c3)n2)ccc2c1OCCO2,0
2115,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CN1CCN(CCOc2cccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)CCC5)n3)c2)CC1,0
2114,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCN4CCOCC4)c3)n2)ccc2c1CCC2,0
2113,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCN4CCOCC4)c3)n2)ccc2c1OCCO2,0
2111,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1N1CCCCC1,0
2154,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Concentration required to inhibit proliferation of murine BaF3 cells expressing human Anaplastic lymphoma kinase (NPM-ALK fusion protein) upon incubation for 2 days with compound dissolved in DMSO in the absence of IL-3; Range 0.01- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CNC(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCCC4)CC3)ccc2OC)ncc1Cl,0
678,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)CCNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
680,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCNC(C)=O)c4)c3n2)cc(OC)c1OC,0
2675,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)C(=O)NC1CCC(n2/c(=N/C(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
2134,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(n2)N(c2cccc(CCC(=O)O)n2)CC3)cc(OC)c1OC,0
2142,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
2140,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCN(C)CC4)CC3)c(OC)cc2OC)ncc1Br,0
2138,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)O)n1,0
2136,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C(C)C)n1,0
2112,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1N1CCN(C)CC1,0
2110,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1N1CCOCC1,0
2068,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCC(F)(F)F)c3S(N)(=O)=O)n2)cc1OC,0
2078,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(F)COc1cccc(Nc2ccnc(Nc3ccc4cnn(C)c4c3)n2)c1S(N)(=O)=O,0
2086,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3ncc(Br)c(Nc4ccc5c(c4S(N)(=O)=O)OCCO5)n3)cc21,0
2085,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2ncc(F)c(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1N(C)C,0
2084,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(F)(F)O4)n2)cc(OC)c1OC,0
2083,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(Cl)COc1cccc(Nc2ccnc(Nc3ccc(OC)c(N(C)C)c3)n2)c1S(N)(=O)=O,0
2082,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCCO4)n2)cc1N(C)C,0
2081,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(Cl)COc1cccc(Nc2ccnc(Nc3ccc4cnn(C)c4c3)n2)c1S(N)(=O)=O,0
2080,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(F)COc1cccc(Nc2ccnc(Nc3ccc(OC)c(N(C)C)c3)n2)c1S(N)(=O)=O,0
2079,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc2ccccc12,0
2077,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCO4)n2)ccc1OC,0
2088,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3ncc(F)c(Nc4ccc5c(c4S(N)(=O)=O)OCCO5)n3)cc21,0
2076,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(F)COc1cccc(Nc2ccnc(Nc3ccc(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
2075,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3ccc4cn[nH]c4c3)n2)ccc2c1OCCO2,0
2074,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3ccc4cn[nH]c4c3)n2)ccc2c1CCC2,0
2073,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1N(C)C,0
2072,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(F)(F)O4)n2)cc1OC,0
2071,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)OCCO5)n3)cc21,0
2070,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1OC,0
2069,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3nccc(Nc4cccc(OC(F)(F)F)c4S(N)(=O)=O)n3)cc21,0
2087,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=C(F)C(F)(F)Oc1cccc(Nc2ccnc(Nc3ccc(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
2089,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCC(F)(F)F)c3S(N)(=O)=O)n2)cc1N(C)C,0
2109,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCC4CCCCO4)c3)n2)ccc2c1OCCO2,0
2100,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(F)(F)O4)n2)ccc1OC,0
2108,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2ncc(Br)c(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1OC,0
2107,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(F)(F)C(F)(F)O4)n2)cc1N(C)C,0
2106,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1OCC1CCCO1,0
2105,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCC(F)=C(F)F)c3S(N)(=O)=O)n2)cc1N(C)C,0
2104,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cc1cc(COc2cccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)OCCO5)n3)c2)no1,0
2103,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(F)(F)C(F)(F)O4)n2)cc1OC,0
2102,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2ncc(F)c(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc(OC)c1OC,0
2101,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CN1CCN(c2cccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)OCCO5)n3)c2)CC1,0
2099,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1C(=O)OC(C)C,0
2090,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCc4cscn4)c3)n2)ccc2c1OCCO2,0
2098,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2ncc(C)c(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc(OC)c1OC,0
2097,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CC(C)OC(=O)COc1cccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)c1,0
2096,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2nccc(Nc3cccc(OC(F)(F)F)c3S(N)(=O)=O)n2)ccc1OC,0
2095,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCC4CCCO4)c3)n2)ccc2c1OCCO2,0
2094,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3nccc(Nc4cccc(OCC(F)=C(F)F)c4S(N)(=O)=O)n3)cc21,0
2093,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)CCC4)n2)ccc1OC,0
2092,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OCC(F)=C(F)F)c3S(N)(=O)=O)n2)cc1OC,0
2091,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1OC,0
2961,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C[C@H]1CN(C(=O)C2CCC(n3/c(=N/C(=O)c4ccccc4)[nH]c4cnc(OCCN5CCCCC5)cc43)CC2)CCN1,0
2963,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3cccc(OC(F)(F)F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2156,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Concentration required to inhibit proliferation of KARPAS-299 lymphoma cells expressing human NPM-ALK fusion protein upon incubation for 2 days with compound dissolved in DMSO in the absence of IL-3; Range 0.01- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC[C@@H]2CN2CCCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
2964,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2cnc(OCCN3CCCCC3)cc2n1C1CCC(C(=O)N2CCNCC2)CC1)c1ccc(F)cc1,0
1884,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc(C)c(C)c3S(N)(=O)=O)n2)cc1OCCCN1CCCC1,0
1882,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1c(C)ccc(Nc2ccnc(Nc3cccc(OCCCN4CCCC4)c3)n2)c1S(N)(=O)=O,0
1880,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc(C)c(OC)c3S(N)(=O)=O)n2)cc1OCCCN1CCCC1,0
1878,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC(C)C)c3S(N)(=O)=O)n2)cc1OCCN1CCN(C)CC1,0
1876,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3cccc(OCCC4CCCN4C)c3)n2)cc1O,0
1874,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,C[N+]1(CCOc2cccc(Nc3nccc(Nc4ccccc4S(N)(=O)=O)n3)c2)C=CN=C1,0
1872,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,C[N+]1(CCOc2cccc(Nc3ncc(Br)c(Nc4cccc(S(N)(=O)=O)c4)n3)c2)C=CN=C1,0
1870,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)n2)cc(OC)c1OC,0
197,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,0
1868,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NC1CCN(c2ccc(Nc3nccc(Nc4ccccc4C(=O)O)n3)cc2)CC1,0
188,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Nc1cccc(Nc2nccc(Nc3ccccc3C(=O)O)n2)c1,0
1885,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(OCCCN4CCCC4)c3)n2)c(S(N)(=O)=O)c1,0
1887,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc(OC)c(OC)c3S(N)(=O)=O)n2)cc1OCCN1CCN(C)CC1,0
1898,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1cc(Cl)c(C)cc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Br,0
730,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CC(C)N1CCN(c2ccc(Nc3nc(Nc4ccc(N5CCOCC5)cc4)ncc3Cl)c3c2CN(C)C3=O)CC1,0
1902,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1cc(C)c(Cl)cc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Br,0
1900,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(C(F)(F)F)c2)ncc1Br,0
1896,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccccc2)ncc1Br,0
1894,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccc(OC)cc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Br,0
1892,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(C)c(OC)c2)ncc1Br,0
1890,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(C(C)C)c2)ncc1Br,0
34,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1,0
41,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3cccc(OCC(F)(F)F)c3S(N)(=O)=O)n2)ccc1C,0
734,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCCCC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
40,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)CCC4)n2)cc(OC)c1OC,0
39,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC(F)(F)F)c3S(N)(=O)=O)n2)cc1OC,0
38,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(N(C)C)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
37,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,C=CCOc1cccc(Nc2ccnc(Nc3ccc(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
735,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
33,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(C)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
31,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Br,0
29,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
27,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc(OC)c1OC,0
42,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCO4)n2)cc1OC,0
732,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(O)CC3)c3c2C(=O)N(C)C3)n1,0
62,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC,0
77,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CCN1CCc2ccc(Nc3nccc(Nc4ccc5c(c4S(N)(=O)=O)OCCO5)n3)cc21,0
76,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3ccc4cc[nH]c4c3)n2)ccc2c1OCCO2,0
68,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OC(C)C4)n2)ccc1C,0
67,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4ccoc4c3S(N)(=O)=O)n2)ccc1C,0
65,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,COc1cccc(Nc2ccnc(Nc3ccc4cc[nH]c4c3)n2)c1S(N)(=O)=O,0
1866,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC1CCOc1cccc(Nc2nccc(Nc3ccccc3O)n2)c1,0
49,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CCN1CCc2ccc(Nc3nccc(Nc4cccc(OC)c4S(N)(=O)=O)n3)cc21,0
48,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCC4)n2)ccc1C,0
47,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCC4)n2)ccc1C,0
1864,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC1CCOc1cccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)c1,0
46,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CC(C)N1CCN(c2ccc(Nc3nc(Cl)ncc3Cl)c3c2CN(C)C3=O)CC1,0
43,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc(OC)c1OC,0
252,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN1CCN(C2CCN(c3ccc(Nc4ncc(Cl)c(Nc5ccccc5S(=O)(=O)C(C)C)n4)c(OC)c3)CC2)CC1,0
3005,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)CNC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCOCC4)cc32)CC1,0
2997,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@H](C(=O)NC(C)C)CC2)c1,0
2998,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)NC3CCCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2999,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)N3CCOCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3000,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)N3CCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3001,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3cccc(C(F)(F)F)c3)[nH]c3ccc(CO)cc32)CC1,0
3002,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2ccc(CN3CCCCC3)cc2n1C12CC3CC(CC(C3)C1)C2)c1ccccc1,0
3003,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2ccc(CN3CCOCC3)cc2n1[C@H]1CC[C@@H](C(=O)N2CCOCC2)CC1)c1ccc(F)cc1,0
3004,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CN1CCN(C(=O)[C@H]2CC[C@@H](n3c(=NC(=O)c4ccc(F)cc4)[nH]c4ccc(CN5CCOCC5)cc43)CC2)CC1,0
3006,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2ccc(CN3CCOCC3)cc2n1[C@H]1CC[C@@H](C(=O)NO)CC1)c1ccc(F)cc1,0
2995,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(C(N)=O)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3007,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]c(=NC(=O)c4ccc(F)cc4)n([C@H]4CC[C@@H](C(=O)O)CC4)c3c2)CC1,0
3008,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)C(=O)N[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
3009,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)C(=O)N[C@H]1CC[C@@H](n2c(=NC(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
3010,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(=O)N[C@H]1CC[C@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
3011,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]c(=NC(=O)c4ccc(F)cc4)n([C@H]4CC[C@H](C(N)=O)CC4)c3c2)CC1,0
3012,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]c(=NC(=O)c4cccc(F)c4)n([C@H]4CC[C@H](C(N)=O)CC4)c3c2)CC1,0
3014,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,N#C[C@]1(c2ccccn2)C[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,0
3015,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(Cc2ccc3[nH]c(=NC(=O)c4ccc(F)cc4)n([C@H]4CC[C@]5(CC4)NC(=O)NC5=O)c3c2)CC1,0
2996,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2cnc(OCCN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)N2CCNCC2)CC1)c1ccc(F)cc1,0
2994,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3cccc(OC(F)(F)F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3017,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@H](C(=O)NC)CC2)c1,0
2979,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(F)cc3F)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
2965,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]/c(=N\C(=O)c2cccc(F)c2)n3C2CCC(C(=O)N3CC(O)C3)CC2)CC1,0
2966,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(F)c(C(F)(F)F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2967,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)c1,0
2968,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]/c(=N\C(=O)c2cccc(F)c2)n3C2CCC(C(=O)N3C[C@@H]4C[C@H]3CN4)CC2)CC1,0
2970,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2972,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccnnc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
2973,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COc1ccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)cc1.O=C(O)C(F)(F)F,0
2976,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc4cc[nH]c4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
2980,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc(C(F)(F)F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
2993,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(S(C)(=O)=O)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2981,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)c1.O=C(O)C(F)(F)F,0
2982,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1ccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)cc1,0
2983,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(C(F)(F)F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2984,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc4cc[nH]c4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2989,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1cc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)ccc1F,0
2990,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(F)c(C(F)(F)F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2991,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1cccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)c1,0
2992,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COc1cc(F)cc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)c1,0
3016,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@H](C(N)=O)CC2)c1,0
3018,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNC(=O)[C@H]1CC[C@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
275,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C)CC3)c3c2C(=O)N(C)C3)n1,0
3055,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3F)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3044,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,Cc1n[nH]c([C@H]2CC[C@@H](n3c(=NC(=O)c4cccc(F)c4)[nH]c4ccc(CO)cc43)CC2)n1,0
3045,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNCC(=O)N1CCC(n2c(=NC(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3048,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]c(=NC(=O)c2cccc(F)c2)n3[C@H]2CC[C@@H](C(=O)N3CC(O)C3)CC2)CC1,0
3050,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNC(=O)[C@]1(O)CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3051,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]c(=NC(=O)c2cccc(F)c2)n3[C@H]2CC[C@@H](C(=O)N3C[C@H]4C[C@@H]3CN4)CC2)CC1,0
725,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(O)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
3052,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc4ccsc4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3053,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3cncs3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3056,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccnnc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
724,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
3057,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C=CCNS(=O)(=O)c1cccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)c1,0
282,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,c1ccc(CNc2ncc3ccn(-c4ccccn4)c3n2)cc1,0
727,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CNC(=O)c1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C(C)C)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
3043,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3cccc(F)c3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
3041,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)S(=O)(=O)N1CCC(n2c(=NC(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3022,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,N#C[C@]1(c2cccc(Br)c2)C[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,0
718,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
3023,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,NC(=O)[C@]1(c2cccc(Br)c2)C[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,0
3026,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,COC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccccc3)[nH]c3cnccc32)CC1,0
3027,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCCCC4)cc32)CC1,0
3028,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](CO)CC1)c1ccc(F)cc1,0
3029,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)CCNC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCCCC4)cc32)CC1,0
3031,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2ccc(CN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)Nc2nccs2)CC1)c1ccc(F)cc1,0
3032,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,Cc1ccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)CC2)cc1,0
719,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
3039,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNS(=O)(=O)N1CCC(n2c(=NC(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3034,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C[C@H]1CN(C(=O)[C@H]2CC[C@@H](n3c(=NC(=O)c4ccccc4)[nH]c4cnc(OCCN5CCCCC5)cc43)CC2)CCN1,0
3035,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,0.1,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@]1(O)CC[C@@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3036,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(C)OC(=O)N1CCC(c2nc(OCCN3CCCCC3)cc3[nH]c(=NC(=O)c4ccccc4)[nH]c23)CC1,0
721,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCNCC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
3038,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,1.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CCS(=O)(=O)N1CCC(n2c(=NC(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
613,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)n1,0
551,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(CCc4cccnc4)c3n2)cc(OC)c1OC,0
552,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(CCc4ccncc4)c3n2)cc(OC)c1OC,0
555,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc([N+](=O)[O-])cc4)c3n2)cc(OC)c1OC,0
558,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1,0
561,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4[N+](=O)[O-])c3n2)cc(OC)c1OC,0
564,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C#N)c4)c3n2)cc(OC)c1OC,0
567,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COC(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
548,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4C#N)c3n2)cc(OC)c1OC,0
420,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCCCC4)CC3)c3c2C(=O)N(C)C3)n1,0
531,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(Cc4cccnc4)c3n2)cc(OC)c1OC,0
533,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4C)c3n2)cc(OC)c1OC,0
538,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(SC)cc4)c3n2)cc(OC)c1OC,0
419,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(OCCN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
543,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccnc(Cl)n4)c3n2)cc(OC)c1OC,0
570,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(C(C)(C)C)cc4)c3n2)cc(OC)c1OC,0
602,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
594,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4C(=O)O)c3n2)cc(OC)c1OC,0
597,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COC(=O)c1cc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc2n1-c1ccccn1,0
416,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCCCC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
592,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCCc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1,0
604,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(C(F)(F)F)cc4)c3n2)cc(OC)c1OC,0
606,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(F)(F)F)c4)c3n2)cc(OC)c1OC,0
609,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)O)c4)c3n2)cc(OC)c1OC,0
577,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
590,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)O)c4)c3n2)cc(OC)c1OC,0
582,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CNC(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
585,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccc(-c2cnc3ccccc3n2)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
529,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C)c4)c3n2)cc(OC)c1OC,0
474,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CC(C)c1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
466,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Brc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
468,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Fc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
471,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
464,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Clc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
477,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
480,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccc(Br)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
484,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1ccc(CO)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
452,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CSc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
444,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
447,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
453,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
456,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
459,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Oc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
517,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccnc4)c3n2)cc(OC)c1OC,0
509,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,c1ccc(-n2ccc3cnc(Nc4cccc5c4CCCC5)nc32)nc1,0
510,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccc(C(N)=O)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
513,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccncc4)c3n2)cc(OC)c1OC,0
519,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(C)cc4)c3n2)cc(OC)c1OC,0
522,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(C)cn4)c3n2)cc(OC)c1OC,0
506,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4nccs4)c3n2)cc(OC)c1OC,0
486,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,c1ccc(-n2ccc3cnc(Nc4ccc5c(c4)OCO5)nc32)nc1,0
495,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1cc(I)ccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
489,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,c1ccc(-n2ccc3cnc(Nc4ccc5[nH]ccc5c4)nc32)nc1,0
492,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccc(I)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
498,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,FC(F)(F)c1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
501,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,FC(F)(F)c1ccc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc1,0
615,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)O)c4)c3n2)cc(OC)c1OC,0
284,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(CNc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC,0
2669,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,NaN,NaN,IC50,μM,<,1.0,"Article; van Erp, Anke E. M.; Hillebrandt-Roeffen, Melissa H. S.; van Houdt, Laurens; Fleuren, Emmy D. G.; van der Graaf, Winette T. A.; Versleijen-Jonkers, Yvonne M. H.; Targeted Oncology; vol. 12; 6; (2017); p. 815 - 826;",Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0
2670,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C=CCNS(=O)(=O)c1cc(C(=O)Nc2nc3ccc(CO)cc3n2C2CCC(C(=O)OC)CC2)ccc1F,0
2671,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,COCCCNS(=O)(=O)c1cc(C(=O)Nc2nc3ccc(CO)cc3n2C2CCC(C(=O)OC)CC2)ccc1F,0
2673,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,1.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CNC(=O)C1(O)CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2674,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,0.1,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)C(=O)NC1CCC(n2/c(=N/C(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,0
2213,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,C/C=C/NS(=O)(=O)c1cccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)c1,0
2211,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,C/C=C/NS(=O)(=O)c1cccc(Nc2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)c1,0
2209,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCCNc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1C,0
2208,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCNc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1C,0
2207,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCCNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1C,0
2206,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCCNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1C,0
2205,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1C,0
2204,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Nc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1C(=O)O,0
2203,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1C(F)(F)F,0
2225,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1000.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1nc(S(=O)(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)cn1C.O=C(O)C(F)(F)F,0
676,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCCN(C)C)c4)c3n2)cc(OC)c1OC,0
288,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,0
666,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCC(C)C)c4)c3n2)cc(OC)c1OC,0
294,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CNS(=O)(=O)c1ccccc1Cn1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
292,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(Nc2ncc3ccn(Cc4cccnc4)c3n2)c(C)c1,0
668,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCN(C)C)c4)c3n2)cc(OC)c1OC,0
671,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NC5CCCC5)c4)c3n2)cc(OC)c1OC,0
2202,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Nc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1C(F)(F)F,0
2201,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1Br,0
2200,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1Cl,0
2168,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Concentration required to inhibit proliferation of KARPAS-299 lymphoma cells expressing human NPM-ALK fusion protein upon incubation for 2 days with compound dissolved in DMSO in the absence of IL-3; Range 0.01- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,0
2176,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cc1cnc(Nc2cccc(OCCN3CCCCC3)c2)nc1Nc1ccc2c(c1S(N)(=O)=O)OCCO2,0
2175,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCN(CC)c1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1OC,0
2174,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2nc(Nc3cccc(OCCN4CCCCC4)c3)ncc2Br)ccc2c1OCCO2,0
2173,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Concentration required to inhibit autophosphorylation of human Anaplastic lymphoma kinase in KARPAS-299 lymphoma cells; Range 0.001- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCC[C@H](C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C2CC2)n1,0
2167,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Concentration required to inhibit autophosphorylation of human Anaplastic lymphoma kinase in KARPAS-299 lymphoma cells; Range 0.001- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN3CCOC[C@@H]3C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
2178,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,NS(=O)(=O)c1c(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)ccc2c1OCCCO2,0
2164,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Concentration required to inhibit autophosphorylation of human Anaplastic lymphoma kinase in KARPAS-299 lymphoma cells; Range 0.001- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,CCS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCC[C@@H](C(N)=O)C3)cc2OC)ncc1Cl,0
2161,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Concentration required to inhibit autophosphorylation of human Anaplastic lymphoma kinase in KARPAS-299 lymphoma cells; Range 0.001- 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2004/80980; (2004); A1;,COc1cc(N2CCN3CCOC[C@@H]3C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
2177,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc2cccnc12,0
2179,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOCCOc1cccc(Nc2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
2199,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)ccc1F,0
2190,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1Br,0
2198,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCc1ccc(Nc2nccc(Nc3ccc4c(c3S(N)(=O)=O)OCCO4)n2)cc1NC,0
2197,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCCNc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1C,0
2196,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCNc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1C,0
2195,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCCNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1C,0
2194,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCCNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1C,0
2193,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1C,0
2192,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cccc(Nc2ccnc(Nc3ccc(N)c(C(=O)O)c3)n2)c1S(N)(=O)=O,0
2191,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cccc(Nc2ccnc(Nc3ccc(N)c(C(F)(F)F)c3)n2)c1S(N)(=O)=O,0
2189,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1Cl,0
2180,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COCCOCCOc1cccc(Nc2ccnc(Nc3ccc4cnn(C)c4c3)n2)c1S(N)(=O)=O,0
2188,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)ccc1F,0
2187,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3cccc(OCCC#N)c3S(N)(=O)=O)n2)ccc1C,0
2186,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1cc(Nc2nccc(Nc3cccc(OCCOC)c3S(N)(=O)=O)n2)ccc1C,0
2185,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C#CCOc1cccc(Nc2ccnc(Nc3ccc(C)c(NC)c3)n2)c1S(N)(=O)=O,0
2184,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,C=CCOc1cccc(Nc2ccnc(Nc3ccc(C)c(NC)c3)n2)c1S(N)(=O)=O,0
2183,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC(F)(F)F)c3S(N)(=O)=O)n2)cc1N(C)C,0
2182,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC(F)F)c3S(N)(=O)=O)n2)cc1N(C)C,0
2181,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,Cn1ncc2ccc(Nc3nccc(Nc4cccc(OCc5ccccc5)c4S(N)(=O)=O)n3)cc21,0
410,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C(C)C)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
646,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCO)c4)c3n2)cc(OC)c1OC,0
638,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCO)c4)c3n2)cc(OC)c1OC,0
639,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
642,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN)c4)c3n2)cc(OC)c1OC,0
648,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NC5CC5)c4)c3n2)cc(OC)c1OC,0
651,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COC(=O)CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)n1,0
635,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
657,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCN)c4)c3n2)cc(OC)c1OC,0
624,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC(C)C)c4)c3n2)cc(OC)c1OC,0
618,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
621,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
627,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CC5)c4)c3n2)cc(OC)c1OC,0
630,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
412,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1CCc2c(N3CCC(N4CCN(C(=O)OC(C)(C)C)CC4)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
2265,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,c1ccc(-n2ccc3cnc(Nc4ccc5cn[nH]c5c4)nc32)nc1,0
2274,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCNS(=O)(=O)c1ccncc1-n1ccc2cnc(Nc3cc(OC)ccc3C)nc21,0
2272,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1CCc2c(N3CCC(N4CCNCC4)CC3)ccc(Nc3nc(Nc4ccccc4F)ncc3Cl)c2C1=O,0
2270,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2cc(N3CC[C@H](N(C)C)C3)ccc2OC)ncc1Cl,0
2268,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,O=C(c1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1)N1CCNCC1,0
2267,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCN(CCO)c1ccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c(C)c1,0
2266,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,c1ccc(-n2ccc3cnc(Nc4ccc5nc[nH]c5c4)nc32)nc1,0
2264,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,c1ccc(-n2ccc3cnc(Nc4ccc5c(c4)NCC5)nc32)nc1,0
2276,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccc(C(=O)O)nc4)c3n2)c1,0
2263,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(N2CCS(=O)(=O)CC2)ccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
2262,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(N2CCSCC2)ccc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
2261,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,Cc1ccc(N2CCOCC2)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
2260,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3c(Cl)cn(-c4ccc(C(=O)O)cc4)c3n2)cc(OC)c1OC,0
2259,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,c1ccc(-n2ccc3cnc(Nc4ccc5cc[nH]c5c4)nc32)nc1,0
2258,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCCNS(=O)(=O)c1cccnc1-n1ccc2cnc(Nc3cc(OC)ccc3C)nc21,0
414,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCCCC4)CC3)c3c2C(=O)N(C)C3)n1,0
659,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COC(=O)CNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
2288,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC#N)c4)c3n2)cc(OC)c1OC,0
662,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CCCC5)c4)c3n2)cc(OC)c1OC,0
2287,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCC#N)c4)c3n2)cc(OC)c1OC,0
2278,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1ccc([N+](=O)O)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
2285,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccc5c(c4)CC(=O)CC5)c3n2)cc(OC)c1OC,0
2283,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCN)c4)c3n2)cc(OC)c1OC,0
2281,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3c(C(=O)O)cn(-c4ccccn4)c3n2)cc(OC)c1OC,0
764,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(S(N)(=O)=O)c3)n2)cc(OC)c1OC,0
737,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
1159,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3C(=O)O)n2)cc(OC)c1OC,0
1124,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3cc[nH]c3c2)n1,0
1122,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)c1,0
1120,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1cccc(Nc2ccnc(Nc3ccc4cn[nH]c4c3)n2)c1,0
1118,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(O)c3)n2)cc(OC)c1OC,0
1116,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(CCO)cc3)n2)cc(OC)c1,0
1114,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc(C)cc3S(N)(=O)=O)n2)cc1,0
1112,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(O)c3)n2)cc1O,0
1110,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc(OC)c1,0
1108,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(S(N)(=O)=O)c3)n2)cc(OC)c1,0
1106,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(S(N)(=O)=O)cc3)n2)cc(OC)c1,0
1104,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(C)c2)ncc1Br,0
1102,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C)cc2)ncc1Br,0
1100,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3O)n2)cc(OC)c1OC,0
1098,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(CO)c2)n1,0
1096,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,c1ccc(Nc2nccc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,0
1125,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC1Oc1cccc(Nc2nccc(Nc3cccc(O)c3)n2)c1,0
1127,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1,0
1144,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1cccc(Nc2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1,0
1157,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)cc1O,0
1156,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(N(C)C)c2)ncc1Br,0
1154,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC(C)C)cc2)ncc1Br,0
1152,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccccc1Nc1ccnc(Nc2cccc(OCCn3cncn3)c2)n1,0
1150,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1,0
1148,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3O)n2)cc1OCCO,0
1146,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3CO)n2)cc(OC)c1OC,0
1141,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1,0
1140,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1cccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)c1,0
1138,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(O)c3)n2)cc1OCCO,0
1136,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ccc3c2)n1,0
1134,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1,0
1132,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc3nn[nH]c3c2)n1,0
1130,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1O,0
1094,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NC(=O)c1ccccc1Nc1ccnc(Nc2cccc(N)c2)n1,0
1042,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)CC3)n1,0
1055,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCC(N4CCCCC4)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1053,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1CCc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1051,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CC(C)N1CCN(c2ccc(Nc3nc(Cl)ncc3Cl)c3c2CCN(C)C3=O)CC1,0
1049,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCNCC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1047,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCNCC4)CC3)c3c2C(=O)N(C)C3)n1,0
1045,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C(C)C)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1036,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3c(n2)N(c2cccnc2)C(O)CC3)cc(OC)c1OC,0
1057,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)CC3)n1,0
1031,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1ccc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)NCC(C)C)n2)c(OC)c1,0
1029,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)N[C@@H](C)C(=O)O)c4)c3n2)cc(OC)c1OC,0
1026,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCCNC(=O)OC(C)(C)C)c4)c3n2)cc(OC)c1OC,0
1023,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN5CCOCC5)c4)c3n2)cc(OC)c1OC,0
1092,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN(C)c1cccc(Nc2nccc(Nc3ccccc3C(=O)O)n2)c1,0
744,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCC(O)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1090,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccc(Nc2ccnc(Nc3cccc(O)c3)n2)cc1,0
1088,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)c1,0
1086,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1cccc(Nc2ccnc(Nc3ccc4cn[nH]c4c3)n2)c1,0
1084,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1cccc(Nc2ccnc(Nc3ccc4[nH]ncc4c3)n2)c1,0
1082,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(O)c3)n2)cc1OC,0
1080,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1O,0
750,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3cc(C(=O)O)n(-c4ccccn4)c3n2)cc(OC)c1OC,0
762,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc4cn[nH]c4c3)n2)cc(OC)c1OC,0
751,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)O)n4)c3n2)cc(OC)c1OC,0
753,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC#N)n4)c3n2)cc(OC)c1OC,0
754,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN)n4)c3n2)cc(OC)c1OC,0
755,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN(C)C)n4)c3n2)cc(OC)c1OC,0
756,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCC#N)n4)c3n2)cc(OC)c1OC,0
757,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCN)n4)c3n2)cc(OC)c1OC,0
1066,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CNc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1C(F)(F)F,0
1065,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,CCc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1NC,0
758,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration against human NMP-ALK (anaplastic lymphoma kinase) expressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 60 min at RT; Range=0.01-1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26158; (2005); A1;,COc1cccc(Nc2ccnc(Nc3ccc(N)c(C)c3)n2)c1S(N)(=O)=O,0
759,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc1OC,0
1296,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCc1cccc(Nc2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)c1S(N)(=O)=O,0
1161,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C)c(C)c2)ncc1Br,0
1259,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccccc1Nc1ccnc(Nc2cccc(OCCN3CCCCC3)c2)n1,0
1258,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(C)c(Nc3cccc(S(N)(=O)=O)c3)n2)cc(OC)c1OC,0
1256,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1c(C)cccc1Nc1ccnc(Nc2cc(OC)c(OC)c(OC)c2)n1,0
1254,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1C,0
1252,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COCCNC(=O)c1ccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc1,0
1250,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCCn3ccnc3)c2)n1,0
1248,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(C)c(Nc3ccccc3S(N)(=O)=O)n2)cc(OC)c1OC,0
1246,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,OCCOc1ccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)cc1,0
1244,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccc(Cl)cc1Nc1ccnc(Nc2cccc(OCCCn3ccnc3)c2)n1,0
1242,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(F)c3S(N)(=O)=O)n2)cc1N(C)C,0
1240,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCOCC4)c3)n2)c1,0
1235,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC(Oc2cccc(Nc3nccc(Nc4cccc(O)c4)n3)c2)CC1,0
1233,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCn3ccnc3)c2)n1,0
1231,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(C)c(Nc3ccc(CCO)cc3)n2)cc(OC)c1OC,0
1229,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCn3ccnc3)c2)n1,0
1261,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)c1,0
1278,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCCCNS(=O)(=O)c1cccc(Nc2nccc(Nc3ccc(CCO)cc3)n2)c1,0
1294,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc1OCCn1ccnc1,0
1293,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(Br)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)cc(OC)c1OC,0
1291,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1I,0
1289,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1ccnc(Nc2ccc(OC)c(OCCn3ccnc3)c2)n1,0
1287,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)NC3CC3)n2)cc(OC)c1OC,0
1285,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3cccc(OC4CCCN(C)CC4)c3)n2)cc1O,0
1283,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(C)c3S(N)(=O)=O)n2)cc1OCCO,0
1263,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(OCCn4ccnc4)c3)n2)cc1O,0
1276,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1cccc(Nc2nc(Nc3cc(OC)c(OC)c(OC)c3)ncc2C)c1,0
1274,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1cnc(Nc2cccc(OCCn3ccnc3)c2)nc1Nc1ccccc1S(N)(=O)=O,0
1272,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(Br)c(Nc3cccc(S(N)(=O)=O)c3)n2)cc(OC)c1OC,0
1270,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccccc1Nc1ccnc(Nc2cccc(OCCN3CCOCC3)c2)n1,0
1268,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cc(C)ccc3S(N)(=O)=O)n2)cc(OC)c1OC,0
1266,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1ccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)c(S(N)(=O)=O)c1,0
1227,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(O)c3)n2)cc1OCCCn1ccnc1,0
1225,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3C(=O)NO)n2)cc(OC)c1OC,0
1176,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1cnc(Nc2ccc3[nH]nnc3c2)nc1Nc1ccccc1S(N)(=O)=O,0
1191,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3O)n2)cc1OCCO,0
1189,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(OCCO)c3)n2)cc1O,0
1187,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cc(OC)c(OC)c(OC)c2)n1,0
1185,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc([N+](=O)[O-])cc3O)n2)cc(OC)c1OC,0
1183,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(O)c3)n2)cc(O)c1C(=O)O,0
1181,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(N3CCOCC3)c2)n1,0
1193,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC1Oc1cccc(Nc2nccc(Nc3cc(Cl)ccc3O)n2)c1,0
1174,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(N(C)C(C)=O)cc3)n2)cc(OC)c1OC,0
1172,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(S(N)(=O)=O)cc3)n2)cc(OC)c1OC,0
1170,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C)c(OC)c2)ncc1Br,0
1168,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C)cc(C)c2)ncc1Br,0
1166,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cc(Cl)ccc3O)n2)cc(OC)c1OC,0
1164,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(OC(C)C)c2)ncc1Br,0
1194,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,OCCc1ccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)cc1,0
1210,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3O)n2)cc1OCCCn1ccnc1,0
1223,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)cc1,0
1221,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc1OCCO,0
1219,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(S(N)(=O)=O)c3)n2)cc1OCCO,0
1217,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2ccnc(Nc3cccc(OCCO)c3)n2)c1S(N)(=O)=O,0
1215,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC(Oc2cccc(Nc3nccc(Nc4ccccc4O)n3)c2)CC1,0
1213,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCn3cncn3)c2)n1,0
1209,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ncc1Br,0
1207,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(C)c3S(N)(=O)=O)n2)cc1N(C)C,0
1205,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc(OC)c1O,0
1203,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3O)n2)cc1OCCn1ccnc1,0
1201,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccc(Cl)cc1Nc1ccnc(Nc2cccc(OCCn3cncn3)c2)n1,0
1199,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cc(C)cc(C)c3O)n2)cc(OC)c1OC,0
1197,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(O)c3)n2)cc1OCCn1ccnc1,0
1020,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NC5CCC(N)CC5)c4)c3n2)cc(OC)c1OC,0
858,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(C)c(C)c4)c3n2)cc(OC)c1OC,0
857,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cccc(Cn2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
854,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,C=Cc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1,0
851,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,C=Cc1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
848,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cn1,0
845,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(Cl)nc4)c3n2)cc(OC)c1OC,0
842,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(F)nc4)c3n2)cc(OC)c1OC,0
839,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1ccc(OCC2CC2)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
836,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)c1ccc(-n2ccc3cnc(Nc4cc(OC)ccc4C)nc32)cc1,0
833,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)ccc3C)nc21,0
830,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(C)c(Nc2ncc3ccn(-c4ccnc(Cl)c4)c3n2)cc1OC,0
861,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,C=Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
877,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCc1ccccc1Cn1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
890,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc([N+](=O)[O-])c4C)c3n2)cc(OC)c1OC,0
888,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cc(C)ccc4[N+](=O)[O-])c3n2)cc(OC)c1OC,0
885,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3c(n2)N(c2ccccn2)C(O)C3O)cc(OC)c1OC,0
883,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc5cccnc45)c3n2)cc(OC)c1OC,0
880,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc5ccccc45)c3n2)cc(OC)c1OC,0
874,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccccc1Cn1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
871,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CNS(=O)(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)ccc3C)nc21,0
868,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CNS(=O)(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)ccc4C)nc32)c1,0
866,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cc(C)cc(C)c4)c3n2)cc(OC)c1OC,0
827,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCCOc1ccc(C)c(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
780,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(Nc2ncc3ccn(-c4ccncc4)c3n2)c(C)c1,0
793,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCOc1ccc(C)c(Nc2ncc3ccn(-c4ccccn4)c3n2)c1,0
792,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(Cc4cccnc4)c3n2)c1,0
790,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccc(C)cn4)c3n2)c1,0
787,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1ccc(O)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
784,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4cccnc4)c3n2)c1,0
778,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccncc4)c3n2)c1,0
775,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4nccs4)c3n2)c1,0
772,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4cccs4)c3n2)c1,0
769,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1C,0
796,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,c1ccc(-n2ccc3cnc(Nc4cccc5[nH]ccc45)nc32)nc1,0
812,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(Nc2ncc3ccn(-c4ccc(OC)nc4)c3n2)c(C)c1,0
824,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(C)c(Nc2ncc3ccn(-c4ccc(C)cn4)c3n2)cc1OC,0
821,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ncccn4)c3n2)cc(OC)c1OC,0
818,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ncccc4[N+](=O)[O-])c3n2)c1,0
815,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccc(OC)nc4)c3n2)c1,0
809,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccc(Cl)nc4)c3n2)c1,0
806,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(Nc2ncc3ccn(-c4ccc(Cl)nc4)c3n2)c(C)c1,0
803,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(Nc2ncc3ccn(-c4ccnc(Cl)c4)c3n2)c(C)c1,0
800,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccnc(Cl)c4)c3n2)c1,0
892,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(C)c([N+](=O)[O-])c4)c3n2)cc(OC)c1OC,0
973,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,CCOCCCNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
986,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCCO)c4)c3n2)cc(OC)c1OC,0
984,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)N5CCOCC5)c4)c3n2)cc(OC)c1OC,0
981,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCN)c4)c3n2)cc(OC)c1OC,0
978,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
972,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)CCNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
988,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4C(=O)NCCCCN(C)C)c3n2)cc(OC)c1OC,0
969,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1ccc(-n2c(C)c3c(C)nnc(C)c3c2C)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
964,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)CCNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)n1,0
961,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CCC5)c4)c3n2)cc(OC)c1OC,0
957,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(NC(C)=O)c(C(=O)O)c4)c3n2)cc(OC)c1OC,0
1005,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCNC(C)=O)c4)c3n2)cc(OC)c1OC,0
1017,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CCC(N)CC5)c4)c3n2)cc(OC)c1OC,0
1014,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCCCN(C)C)c4)c3n2)cc(OC)c1OC,0
1011,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCOCCCNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
1008,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CCN(C)CC5)c4)c3n2)cc(OC)c1OC,0
1002,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCCCN)c4)c3n2)cc(OC)c1OC,0
999,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC(CC(C)C)C(=O)O)c4)c3n2)cc(OC)c1OC,0
996,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4C(=O)N(CCO)CCO)c3n2)cc(OC)c1OC,0
993,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)N5CCOCC5)c4)c3n2)cc(OC)c1OC,0
909,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccccc4COC(C)=O)c3n2)cc(OC)c1OC,0
922,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
921,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)N(C)C)c4)c3n2)cc(OC)c1OC,0
918,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4cccc(C(=O)NCCN(C)C)c4)c3n2)c1,0
915,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)Cc1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21,0
912,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCNS(=O)(=O)c1ccccc1-n1ccc2cnc(Nc3cc(O)ccc3C)nc21,0
906,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(-c5nnn[nH]5)c4)c3n2)cc(OC)c1OC,0
903,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
900,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)N(C)C)n4)c3n2)cc(OC)c1OC,0
897,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,Cc1ccc(OC2CCCCCC2)cc1Nc1ncc2ccn(-c3ccccn3)c2n1,0
925,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3c(Cl)cn(-c4cccc(C(=O)O)c4)c3n2)cc(OC)c1OC,0
955,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCO)c4)c3n2)cc(OC)c1OC,0
941,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCc5nnn[nH]5)c4)c3n2)cc(OC)c1OC,0
952,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC(=O)O)c4)c3n2)cc(OC)c1OC,0
949,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COC(=O)CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
946,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
940,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,CCCNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1,0
937,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)N(C)C)c4)c3n2)cc(OC)c1OC,0
934,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(Cc5nnn[nH]5)c4)c3n2)cc(OC)c1OC,0
929,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4ccc(N)c(C(=O)O)c4)c3n2)cc(OC)c1OC,0
1550,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCCN(C)C)n1,0
1544,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1545,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1298,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccc(S(N)(=O)=O)cc3)n2)cc1OCCn1ccnc1,0
1548,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CC[C@H](N(C)C)C2)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1551,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1542,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC2CC(C)(C)N(C)C(C)(C)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1553,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCCCO)n1,0
1555,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCCC(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1557,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(C(N)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1524,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCC(O)CC3)ccc2OC)ncc1Br,0
1532,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)(C)C)n1,0
1526,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC[C@@H]2CCCN2C)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1527,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC[C@H]2CCCN2C)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1529,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(OCCN2CCOCC2)cc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1533,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCCC(C)(C(N)=O)C3)cc2OC)ncc1Cl,0
1540,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OCCN2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1535,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1537,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(OCCN2CCOCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1559,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N2CCNCC2)n1,0
1585,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(C(N)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1579,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COCCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc5c4C(=O)N(C)C5)n3)c(OC)c2)C[C@@H]1C,0
1581,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COCCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc5c4C(=O)N(C)C5)n3)c(OC)c2)C[C@H]1C,0
1583,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OCC2CC2)ncc1Cl,0
1561,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OCCN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1588,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCCC(C)(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1589,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OCCN2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1591,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCOCC4)CC3)ccc2OC)ncc1Br,0
1593,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCCC(C)(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1578,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OCCCN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1576,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC2CC(C)(C)N(C)C(C)(C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1574,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OCCN2CCN(C(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1572,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OCCN2CCCCC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1570,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N2CCN(C)CC2)n1,0
1568,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCOCC3)c(OC)cc2OC)ncc1Br,0
1566,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@@](C)(C(N)=O)C3)cc2OC)ncc1Cl,0
1564,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC[C@](C)(C(N)=O)C3)cc2OC)ncc1Cl,0
1453,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(N(C)C)C2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1479,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1473,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CN[C@H]1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,0
1475,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCCN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1477,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCN(C)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1471,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CN[C@@H]1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,0
1481,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC2CCN(C(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1483,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCCCC3)ccc2OC)ncc1Br,0
1485,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(OC2CCN(C(C)C)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1470,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)c(F)cc2OC)ncc1Br,0
1522,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCOCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1461,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1455,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(OC2CCN(C)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1457,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2S(=O)(=O)CCC3)n1,0
1459,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1463,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(N3CCOCC3)cc2OC)ncc1Br,0
1465,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCOCC3)c(OC)cc2OC)ncc1Br,0
1467,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)CC(C)C)n1,0
1487,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCN(C)CC2)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1489,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC(C)C)ncc1Cl,0
1514,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(OCCN2CCOCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
1508,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)(C)C)n1,0
1509,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN[C@@H]1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,0
1511,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN[C@H]1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC(C)C)n3)c(OC)c2)C1,0
1515,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCCN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,0
1517,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)CC(C)C)n1,0
1519,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1506,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1504,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCCO)n1,0
1502,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN1CCc2cccc(Nc3nc(Nc4ccc(N5CCOCC5)cc4OC)ncc3Cl)c2C1=O,0
1500,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCOc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1498,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1496,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1494,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC)c(N2CCOCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1492,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1595,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC[C@](C)(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1760,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCNCC4)CC3)c3c2C(=O)N(C)CC3)n1,0
1754,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1755,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(C4CCNCC4)CC3)c3c2C(=O)N(C)C3)n1,0
1757,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(C4CCN(C)CC4)CC3)c3c2C(=O)N(C)C3)n1,0
1761,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(C5CCNCC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1752,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCNCC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1763,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C)CC3)c3c2C(=O)N(C)CC3)n1,0
1765,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(C5CCN(C)CC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1767,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCNCC5)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1597,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC[C@@](C)(C(N)=O)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1742,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1736,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCNCC3)c3c2C(=O)N(C)CC3)n1,0
1737,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1CCN(c2ccc(Nc3nc(Nc4ccccc4F)ncc3Cl)c3c2CCN(C)C3=O)CC1,0
1739,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1CCc2c(N3CCNCC3)ccc(Nc3nc(Nc4ccccc4F)ncc3Cl)c2C1=O,0
1743,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCNCC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1750,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCC(N4CCN(C(=O)OC(C)(C)C)CC4)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1745,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C)CC3)c3c2C(=O)N(C)CC3)n1,0
1747,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(F)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCNCC3)c3c2C(=O)N(C)CC3)n1,0
1769,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1795,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c3c2C(=O)N(C)CC3)n1,0
1789,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(C4CCN(C)CC4)CC3)c3c2C(=O)N(C)C3)n1,0
1791,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(C4CCNCC4)CC3)c3c2C(=O)N(C)C3)n1,0
1793,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCNCC4)CC3)c3c2C(=O)N(C)CC3)n1,0
1771,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(C5CCN(C)CC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
742,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
740,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CC[C@@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C(C)C)CC3)c3c2C(=O)N(C)C3)n1,0
1830,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1000.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1cc2cc(c1)Nc1nc(ncc1Cl)Nc1cccc(c1)CC2)C1CCC1.O=C(O)C(F)(F)F,0
1788,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCNCC4)CC3)c3c2C(=O)N(C)C3)n1,0
1786,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c3c2C(=O)N(C)C3)n1,0
1784,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1782,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCNCC5)CC4)c4c3C(=O)N(C)CC4)n2)c(OC)c1,0
1780,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN4CCOC[C@H]4C3)c3c2C(=O)N(C)C3)n1,0
1778,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1776,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(N5CCNCC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1774,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCC(C5CCNCC5)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1734,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCN(C)CC3)c3c2C(=O)N(C)CC3)n1,0
1621,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1615,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCC(O)CC2)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1617,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1619,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(N3CCCCC3)CC2)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1630,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1623,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Cl,0
1625,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1627,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1614,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCC(O)CC2)ccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Cl,0
1612,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(N3CCN(C)CC3)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1610,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(N3CCCCC3)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1608,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN3CCOC[C@@H]3C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1606,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCN3CCOC[C@H]3C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1604,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2cc(N3CCOCC3)ccc2OC)ncc1Cl,0
1602,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(N3CCN(C)CC3)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
1600,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(N3CCOCC3)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1631,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1732,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(OC3CCN(C(=O)OC(C)(C)C)CC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1724,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with DMSO dissolved compound for 2 days; Range = 0.001 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COc1ccccc1Nc1ncc(Cl)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c3c2C(=O)N(C)C3)n1,0
1650,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN1CCc2cccc(Nc3nc(Nc4ccc(N5CCC(N6CCN(C)CC6)CC5)cc4OC)ncc3Cl)c2C1=O,0
1719,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CC(C)N1CCN(c2ccc(Nc3nc(Nc4ccccc4F)ncc3Cl)c3c2CCN(C)C3=O)CC1,0
1721,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,COCCOc1ccc(Nc2ncc(Cl)c(Nc3ccc(N4CCN(C(C)C)CC4)c4c3C(=O)N(C)C4)n2)c(OC)c1,0
1725,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1CCc2c(F)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1727,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(OCCN3CCOCC3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1729,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with DMSO dissolved compound for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21457; (2006); A3;,CN1Cc2c(N3CCN4CCOC[C@H]4C3)ccc(Nc3nc(Cl)ncc3Cl)c2C1=O,0
1648,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2S(=O)(=O)CCC3)n1,0
1646,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1cc(N2CCN(C)CC2)ccc1Nc1nc(Nc2ccc(N3CC[C@H](N(C)C)C3)cc2OC)ncc1Cl,0
1644,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1642,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1640,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)CC3)n1,0
1638,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2S(=O)(=O)CCC3)n1,0
1636,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1634,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CC[C@H](N(C)C)C2)ccc1Nc1ncc(Cl)c(Nc2cccc3c2C(=O)N(C)C3)n1,0
1451,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC3CCN(C(C)C)CC3)ccc2OC)ncc1Br,0
1391,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(N4CCN(C)CC4)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
1392,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(OCCN4CCCC4)c3)n2)c(S(N)(=O)=O)c1,0
1394,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CC(C)Oc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)c1S(N)(=O)=O,0
1396,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCOc1ccc(Nc2ccnc(Nc3ccc(C)c(OCCN4CCCC4)c3)n2)c(S(N)(=O)=O)c1,0
1398,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1OCCCN1CCOCC1,0
1389,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)c1S(N)(=O)=O,0
1450,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCC(O)CC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1400,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCN(Cc5ccccc5)CC4)c3)n2)c1S(N)(=O)=O,0
1448,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCOCC2)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1402,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCN(C5CCCC5)CC4)c3)n2)c1S(N)(=O)=O,0
1367,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CC(=O)N(C)c1ccc(Nc2nccc(Nc3ccc(S(=O)(=O)NCCOCCO)cc3)n2)cc1,0
1377,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(N4CCOCC4)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
1369,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(OCCN4CCCCC4)c3)n2)cc1O,0
1370,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(S(=O)(=O)NCCOCCO)cc3)n2)cc(OC)c1OC,0
1372,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3O)n2)cc1OCCN1CCCCC1,0
1374,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2ccnc(Nc3ccc(C)c(OCCN4CCCC4)c3)n2)c1S(N)(=O)=O,0
1378,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)c(S(N)(=O)=O)c1,0
1387,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1cc(Br)ccc1Nc1ccnc(Nc2cccc(OCCN3CCCCC3)c2)n1,0
1380,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCN(C)CC4)c3)n2)c1S(N)(=O)=O,0
1382,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(C)c3S(N)(=O)=O)n2)cc1OCCC1CCCN1C,0
1384,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc1OCCN1CCCCC1,0
1446,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCCCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1444,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCOCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)NC(C)C)n1,0
1414,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(Nc2ncc(Cl)c(Nc3cccc4c3C(=O)N(C)C4)n2)c(OC)c1,0
1411,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN5CCCC5)n4)c3n2)cc(OC)c1OC,0
1429,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1ccc(Nc2ncc(Cl)c(Nc3cccc4c3S(=O)(=O)CCC4)n2)c(OC)c1,0
1412,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)N5CCC[C@H]5C(=O)O)c4)c3n2)cc(OC)c1OC,0
1428,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,0
1426,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C(C)C)n1,0
1424,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNC(=O)c1ccc(OC)c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)NCC(C)C)n2)c1,0
1415,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc3c(cc2OC)OCC(=O)N3C)ncc1Br,0
1422,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2-c2nn[nH]n2)n1,0
1420,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(N2CCOCC2)cc1Nc1ncc(Br)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
1417,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,COc1ccc(C(N)=O)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1,0
1431,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in murine BaF3 cells upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N(C)C)C3)ccc2OC)ncc1Br,0
1410,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of murine Ba/F3 cells upon incubation for 2 days at RT with the compound dissolved in 1 DMSO; Range is 0.01 - 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)N5CCCC5C(=O)O)c4)c3n2)cc(OC)c1OC,0
1442,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CCN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,0
1440,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(O)CC3)ccc2OC)ncc1Br,0
1404,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1ccc(C)c(Nc2ncc3ccn(-c4ccc(C(=O)O)cc4)c3n2)c1,0
1405,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc5c4CC(=O)CC5)c3n2)cc(OC)c1OC,0
1406,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,Inhibitory activity against human Nucleophosmin-ALK (NPM-ALK) mediated proliferation of KARPAS-299 cells upon incubation for 2 days at RT with compound dissolved in 1 DMSO; Range is 0.001-1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; US2007/225306; (2007); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC(C)C(=O)O)c4)c3n2)cc(OC)c1OC,0
1438,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC[C@H]3CCCN3C)ccc2OC)ncc1Br,0
1436,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC[C@@H]3CCCN3C)ccc2OC)ncc1Br,0
1434,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Antiproliferative activity against growth signal mechanism mediated by human neuroplasmin-anaplastic lymphoma kinase overexpressed in human KARPAS-299 lymphoma cell line upon incubation with the compound dissolved in DMSO for 2 days; Range = 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2006/21454; (2006); A2;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCCCC3)ccc2OC)ncc1Br,0
1408,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory concentration of the compound against Anaplastic lymphoma kinase (ALK) autophosphorylation expressed in human KARPAS-299 cell line; Range = 0.01 to 1 uM,NaN,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/80393; (2005); A1;,COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCCN)c4)c3n2)cc(OC)c1OC,0
1328,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3ccc(OC)c(OCCCn4ccnc4)c3)n2)cc1O,0
1344,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1cccc(Nc2nc(Nc3ccc(OC)c(OCCn4ccnc4)c3)ncc2C)c1,0
1338,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCN3CCOCC3)c2)n1,0
1340,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCN3CCCCC3)c2)n1,0
1342,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Br,0
1315,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)NCCO)n2)cc(OC)c1OC,0
1346,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1cc(F)ccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Br,0
1348,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3cccc(-c4ccccc4)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
1350,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3S(N)(=O)=O)n2)cc1OCCCn1ccnc1,0
1317,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(C)c(OC)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
1318,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccc(Cl)cc1Nc1ccnc(Nc2cccc(OCCN3CCCCC3)c2)n1,0
1337,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ncc(C)c(Nc3ccc(S(N)(=O)=O)cc3)n2)cc1OCCn1ccnc1,0
1335,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCN(c2cccc(Nc3nccc(Nc4cccc(Cl)c4S(N)(=O)=O)n3)c2)CC1,0
1320,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3ccccc3O)n2)cc1OCCN1CCCCC1,0
1322,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2ncc(Cl)c(Nc3cccc(C)c3S(N)(=O)=O)n2)cc(OC)c1OC,0
1333,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,O=S(=O)(NCCO)c1ccccc1Nc1ccnc(Nc2cccc(OCCn3ccnc3)c2)n1,0
1331,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(O)c3)n2)cc1OCCN1CCCCC1,0
1324,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2ccnc(Nc3cccc(OCCN4CCCCC4)c3)n2)cc1O,0
1326,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC(Oc2cccc(Nc3nccc(Nc4ccccc4S(N)(=O)=O)n3)c2)CC1,0
1301,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCc1cnc(Nc2cc(OC)c(OC)c(OC)c2)nc1Nc1cccc(S(=O)(=O)NC)c1,0
1357,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,NS(=O)(=O)c1ccccc1Nc1ccnc(Nc2cccc(OCCN3CCNCC3)c2)n1,0
1358,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1cccc(Nc2ccnc(Nc3cccc(OCCC4CCCN4C)c3)n2)c1S(N)(=O)=O,0
1302,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CN1CCCC(Oc2cccc(Nc3nccc(Nc4cc(Cl)ccc4O)n3)c2)CC1,0
1360,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1C(F)(F)F,0
1362,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cccc(Nc2ccnc(Nc3cccc(OCCN4CCCC4)c3)n2)c1S(N)(=O)=O,0
1364,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(OC)c3S(N)(=O)=O)n2)cc1N1CCOCC1,0
1355,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1ccc(Nc2ccnc(Nc3cccc(OCCN4CCCC4)c3)n2)c(S(N)(=O)=O)c1,0
1308,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,CCc1cnc(Nc2cc(OC)c(OC)c(OC)c2)nc1Nc1ccccc1S(N)(=O)=O,0
1313,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Cc1cccc(Nc2ccnc(Nc3cccc(OCCn4ccnc4)c3)n2)c1S(N)(=O)=O,0
1352,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing murine BaF3 cells upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1cc(Nc2nccc(Nc3ccc(-c4ccccc4)cc3S(N)(=O)=O)n2)cc(OC)c1OC,0
1311,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3O)n2)cc1OCCCn1ccnc1,0
1307,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,COc1ccc(Nc2nccc(Nc3cccc(S(N)(=O)=O)c3)n2)cc1OCCn1ccnc1,0
1305,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound (dissolved in DMSO) against growth of human NPM-ALK overexpressing human KARPAS-299 cell line upon incubation for two days; Range is ~ 0.01 uM - 1 uM,human,IC50,µM,=,1.0,Patent; Novartis (w/o Sandoz); NOVARTIS AG; WO2005/26130; (2005); A1;,Oc1ccc(Cl)cc1Nc1ccnc(Nc2cccc(OCCN3CCOCC3)c2)n1,0
1904,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1100.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,CC(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1944,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1108.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1Cc2cccc(c2)Nc2nc(ncc2Cl)Nc2cccc1c2,0
2246,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1150.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=C(c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2)N1CCN(c2ccccc2)CC1,0
1937,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1200.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cc1nocc1S(=O)(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1946,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1210.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1CCc2cccc(c2)Nc2ncc(Cl)c(n2)Nc2cccc1c2,0
1948,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1220.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1nccs1)c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
1853,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase using (0.5 uM) Biotin-KKKGPWLEEEEEAYGWLDF-amide as substrate and in presence of 90 uM ATP upon incubation in 50 mM Tris,pH 7.8 for 2 h at 25 degree C",NaN,IC50,nM,=,1230.0,Patent; INCYTE CORP; WO2010/85597; (2010); A1;,Clc1cnc2nc1NCc1cccc(c1)OCCc1cccc(c1)N2,0
2252,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1250.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)NCCCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
2251,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1332.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)CNCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1818,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1370.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1(=O)CCc2cccc(c2)Nc2ncc(Cl)c(n2)Nc2cccc1c2,0
1903,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1440.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,COC(=O)c1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
2255,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1460.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)NCCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1837,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1500.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1)c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
2217,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1500.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
175,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against 1 nM wild type human ANAPLASTIC LYMPHOMA KINASE expressed in SF9 insect cells using 2.5 uL Ulight-CKKSRGDYMTMQIG as substrate in presence of 100 uM ATP upon incubation in 50 mM Hepes, pH 7.5 for 90 mins at RT by LANTHANIDE CHELATE EXCITE TIME-RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER (LANCE TR-FRET) ASSAY",NaN,IC50,nM,=,1510.0,Patent; ASCENTAGE PHARMACEUTICAL GROUP CO LTD; WO2015/127629; (2015); A1;,Cn1c2cc(N3CCC(N4CCOCC4)CC3)ccc2c(=O)c2c3ccc(C#N)cc3[nH]c21,0
1856,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase using (0.5 uM) Biotin-KKKGPWLEEEEEAYGWLDF-amide as substrate and in presence of 90 uM ATP upon incubation in 50 mM Tris,pH 7.8 for 2 h at 25 degree C",NaN,IC50,nM,=,1530.0,Patent; INCYTE CORP; WO2010/85597; (2010); A1;,Clc1cnc2nc1NCc1cccc(c1)OCCc1cccc(c1)N2.O=C(O)C(F)(F)F,0
2226,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1530.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.Clc1cnc2nc1Nc1cc(cc(CN3CCNCC3)c1)CCc1cccc(c1)N2,0
1945,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1743.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1CCOc2cccc(c2)Nc2ncc(Cl)c(n2)Nc2cccc1c2,0
1906,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1800.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,COCC(=O)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
1939,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1800.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S(=O)(Cc1ccccc1)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2,0
1952,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against human recombinant Anaplastic lymphoma kinase (20 nM) upon incubation in 50 mM HEPES buffer, pH 7.5 in the presence of ATP (80 uM) and 33P-gamma-ATP (1 nM)",human,IC50,µM,=,1.87,Patent; NERVIANO MEDICAL SCIENCES S.R.L.; WO2010/69966; (2010); A1;,O=C(Nc1n[nH]c2cc(OCc3cc(F)cc(F)c3)ccc12)c1ccccc1,0
1811,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1900.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=S1(=O)Nc2cccc(c2)Nc2ncc(Cl)c(n2)Nc2cccc1c2,0
1851,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1940.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2[nH]ccc2c1)c1cc2cc(c1)OCCSc1cccc(c1)Nc1nc(ncc1Cl)N2.O=C(O)C(F)(F)F,0
1850,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,1956.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc(CCO)cc1)c1cc2cc(c1)Nc1nc(ncc1Cl)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,0
1973,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 1000-1999 nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1ccc(-c2nc3[nH]nc(C)c3c3cc(OCC4CCN(C)CC4)c(OC)c(F)c23)cc1Cl,0
1713,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 1000-1999 nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,COc1ccc(Cc2n[nH]c3nc(-c4ccc(O)cc4)c4cc(OC)c(OC)cc4c23)cc1OC,0
1704,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range=1000-1999nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)c(O)c3)nc3[nH]nc(Cc4ccccc4)c3c2cc1OC,0
2044,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range=1000-1999nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,Cc1n[nH]c2nc(-c3cn(C)c(=N)s3)c3c(F)cc(O)c(F)c3c12,0
1698,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range=1000-1999nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cccc(Cc2n[nH]c3nc(-c4ccc(O)cc4)c4cc(OC)c(OC)cc4c23)c1,0
1692,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range=1000-1999nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,CC(=O)Nc1ncc(-c2nc3[nH]nc(C)c3c3c(F)c(O)cc(F)c23)s1,0
1684,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory activity against ALK was determined by measuring the incorporation of radioactive phosphate derived from 32P-ATP into substrate polyglutamic acid, tyrosine, 4: 1 (pEY) by luciferase coupled chemiluminescent kinase assay; Range=1000-1999nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; WO2005/9389; (2005); A2;,COc1cc2c(-c3ccc(O)c(OC(F)F)c3)nc3[nH]nc(C)c3c2cc1OC,0
1975,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration against human ALK (12 nM) in presence of 1 uM ATP, 4 uM poly-AEKY upon incubation in 20 nM Tris-HCl, pH 7.5 at ambient temperature for 2 h by using luciferase-coupled chemiluminescent kinase assay; Range 1000-1999 nM",NaN,IC50,nM,=,1999.0,Patent; EXELIXIS INC; US2007/32515; (2007); A1;,Cc1n[nH]c2nc(-c3ccc(N)cc3)c3c(F)cc(O)c(F)c3c12,0
2912,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCCN2CCCC2=O)cs1,0
3065,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(NCc1ncc(C(=O)NCCc2cccc(Cl)c2)s1)OCc1ccc(OC(F)(F)F)cc1,0
3064,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)Nc2ccc(F)cc2F)cs1,0
3063,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@@H]1COC[C@H](C)N1C(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
3062,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSCC[C@H](NC(=O)c1ccccc1)C(=O)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1,0
2928,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(F)cc2C(F)(F)F)cs1,0
2925,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCN(CC)C(=O)C1CCCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)C1,0
2924,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1cc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)ccc1OC,0
2921,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)(C)OC(=O)NC1CCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CC1,0
2872,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1cccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2916,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2c[nH]c3ccccc23)co1,0
2915,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)(C)OC(=O)NC1CCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)C1,0
2913,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCC(c2ccccc2)c2ccccc2)cs1,0
2882,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCCc3ccccc32)co1,0
2910,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCCCN(CCC#N)C(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2885,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1OC,0
2907,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CN(C(=O)OC(C)(C)C)C1CCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)C1,0
2906,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CC[C@@H]3CCCC[C@@H]3C2)cs1,0
2877,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC(Cc2ccccc2)c2ccccc2)cs1,0
2905,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CC[C@H]3CCCC[C@@H]3C2)cs1,0
2904,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOC(=O)N1CCC(NC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CC1,0
2901,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCN2CCCCC2)cs1,0
2893,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CCC3CCCCC3C2)cs1,0
2869,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCC(c2ccccc2)c2ccccc2)co1,0
2890,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCCN2CCOCC2)cs1,0
2880,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CCCC3CCCCC32)cs1,0
2886,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(Cl)c(Cl)c2)co1,0
2876,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC1CN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CCN1c1ccccc1,0
2909,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(N2CCN(C(=O)c3csc(CNC(=O)COc4ccc(OC(F)(F)F)cc4)n3)CC2C)cc1,0
2867,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)N2CCN(c3ccccn3)CC2)cs1,0
2822,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2784,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC1CC(C)CN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)C1,0
2785,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2cccnc2)cs1,0
2787,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCC(F)(F)F)cs1,0
2788,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccc2Cl)co1,0
2789,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,Cc1ccccc1CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2792,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(NCCc1cccc(Cl)c1)c1csc(CNC(=O)C2(c3ccc(Cl)cc3)CC2)n1,0
2798,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(=O)NCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2801,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(F)cc2)co1,0
2803,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@H](CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2804,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CNC(=O)c2csc(CNC(=O)Cc3ccc4ccccc4c3)n2)c1OC,0
2805,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccc2)co1,0
2806,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC1CCCCC1NC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2811,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccn2)co1,0
2814,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCC2CCCO2)cs1,0
2815,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccncc2)co1,0
2782,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)c1ccccc1,0
2781,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccncc2)cs1,0
2778,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC1CCCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)C1,0
2747,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2860,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCOc1ccc(NC(=O)NCc2nc(C(=O)NCc3cccc(OC)c3OC)cs2)cc1,0
2735,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)C/C=C/c2ccccc2)n1,0
2737,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(Cl)cc2)n1,0
2738,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2742,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(C/C=C/c1ccccc1)NCc1nc(C(=O)NCCc2ccccc2F)cs1,0
2746,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CSc1ccc(CC(=O)NCc2nc(C(=O)NCCc3cccc(Cl)c3)cs2)cc1,0
2748,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)COc2ccc(Br)cc2)n1,0
2777,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NC2CCCC2)cs1,0
2754,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COCCCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2758,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@@H](NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)C(C)(C)C,0
2763,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccccc2)co1,0
2770,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccccc1CNC(=O)c1csc(CNC(=O)Cc2ccc3ccccc3c2)n1,0
2771,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccco2)cs1,0
2776,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CC(C)CCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2820,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCCCCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2762,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(Br)cc1)NCc1nc(C(=O)NCCc2ccccc2F)cs1,0
2846,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccccc2Cl)co1,0
2859,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,NC(=O)C1CCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CC1,0
2844,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCN2CCCC2)cs1,0
2828,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCc2ccc(Cl)cc2)cs1,0
2836,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,C[C@H](NC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1)C1CCCCC1,0
2837,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1cccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)c1,0
2850,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CN(C)c1ccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2838,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCN1CCCC1CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2853,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,COc1ccc(CCNC(=O)c2coc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1,0
2834,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCCC1CCN(C(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)CC1,0
2839,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(Cl)cc2)co1,0
2854,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CCOc1ccccc1CNC(=O)c1coc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
2855,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,O=C(COc1ccc(OC(F)(F)F)cc1)NCc1nc(C(=O)NCCc2ccc(Br)cc2)co1,0
2857,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration against baculovirus expressed human ALK (12 nM) in presence of poly-AEKY(4 uM) in Tris-HCl buffer, pH 7.5 upon incubation for 2 h at ambient temperature measured as percent ATP remaining by luciferase-coupled chemiluminescent kinase assay; range is > 500 to < 2000 nM",human,IC50,nM,<,2000.0,Patent; EXELIXIS INC; WO2005/97765; (2005); A1;,CN1CCCC1CCNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1,0
1852,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,2037.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.c1cc2cc(c1)Nc1ccnc(n1)Nc1cccc(c1)CC2,0
1822,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,2050.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=C1CCc2cccc(c2)Nc2nc(ncc2Cl)Nc2cccc(c2)N1,0
1857,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase using (0.5 uM) Biotin-KKKGPWLEEEEEAYGWLDF-amide as substrate and in presence of 90 uM ATP upon incubation in 50 mM Tris,pH 7.8 for 2 h at 25 degree C",NaN,IC50,nM,=,2050.0,Patent; INCYTE CORP; WO2010/85597; (2010); A1;,Clc1cnc2nc1NCc1cccc(c1)OCCOc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1922,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,2200.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Cl.O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)C1CCC1,0
2015,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (Disssolved in DMSO) against human recombinant wild type ALK upon incubation in presence of 30 uM ATP in 50 mM HEPES, pH 7.0 for 90 mins at RT was determined by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) FRET ASSAY",NaN,IC50,nM,=,2269.0,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; WO2015/50989; (2015); A2;,C[C@@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)OCCOc2ccc(F)cc21,0
36,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,Inhibitory concentration of the compound against recombinant human ALK was determined by radiometric kinase assay,human,IC50,µM,=,2.3,"Article; Yang, Jiao; Wang, Li-Jiao; Liu, Jing-Jing; Zhong, Lei; Zheng, Ren-Lin; Xu, Yong; Ji, Pan; Zhang, Chun-Hui; Wang, Wen-Jing; Lin, Xing-Dong; Li, Lin-Li; Wei, Yu-Quan; Yang, Sheng-Yong; Journal of Medicinal Chemistry; vol. 55; 23; (2012); p. 10685 - 10699;",CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1,0
2215,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,2370.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(NCc1ccncc1)c1cc2cc(c1)Nc1nc(ncc1Cl)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,0
2017,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (Disssolved in DMSO) against human recombinant wild type ALK upon incubation in presence of 30 uM ATP in 50 mM HEPES, pH 7.0 for 90 mins at RT was determined by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) FRET ASSAY",NaN,IC50,nM,=,2371.0,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; WO2015/50989; (2015); A2;,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)NC(=O)COc2ccc(F)cc21,0
1838,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,3600.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1)Nc1cc2cc(c1)Nc1nc(ncc1Cl)Nc1cccc(c1)CC2.O=C(O)C(F)(F)F,0
1802,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,4190.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,Clc1cnc2nc1Nc1cccc(c1)COc1cccc(c1)N2.O=C(O)C(F)(F)F,0
1829,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,4400.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccccc1)c1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2.O=C(O)C(F)(F)F,0
3037,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2cnc(OCCN3CCCCC3)cc2n1C1CCNCC1)c1ccccc1,0
3024,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,NC(=O)[C@]1(c2cccc(Br)c2)C[C@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,0
2986,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccc4ccn(C)c4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2953,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]/c(=N\C(=O)c2cccc(F)c2)n3C2CCC(C(=O)O)CC2)CC1,0
2987,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3ccccn3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2971,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccccn3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
3033,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,C[C@H]1CN(C(=O)[C@H]2CC[C@@H](n3c(=NC(=O)c4ccc(F)cc4)[nH]c4cnc(OCCN5CCCCC5)cc43)CC2)CCN1C(=O)OC(C)(C)C,0
2978,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3ccc4ccn(C)c4c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
3030,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2ccc(CN3CCOCC3)cc2n1[C@H]1CC[C@@H](C(=O)O)CC1)c1ccc(F)cc1,0
3020,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,NC(=O)[C@H]1CC[C@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3021,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNC(=O)[C@H]1CC[C@H](n2c(=NC(=O)c3cc(F)cc(F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3025,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,O=C(N=c1[nH]c2cnc(OCCN3CCCCC3)cc2n1[C@H]1CC[C@@H](C(=O)O)CC1)c1ccccc1,0
2969,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,C[C@H]1CN(C(=O)C2CCC(n3/c(=N/C(=O)c4ccc(F)cc4)[nH]c4cnc(OCCN5CCCCC5)cc43)CC2)CCN1C(=O)OC(C)(C)C,0
3019,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,NC(=O)[C@H]1CC[C@H](n2c(=NC(=O)c3cc(F)cc(F)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2985,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNc1ccc(C(=O)N=c2[nH]c3cnc(OCCN4CCCCC4)cc3n2[C@H]2CC[C@@H](C(=O)NC(C)C)CC2)cc1,0
3046,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CN(CC(=O)N1CCC(n2c(=NC(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1)C(=O)OC(C)(C)C,0
3054,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3cccc(S(C)(=O)=O)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
3013,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,N#C[C@]1(c2ccccn2)C[C@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)C1,0
3049,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CNC(=O)[C@]1(O)CC[C@H](n2c(=NC(=O)c3ccc(F)cc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
2934,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(=O)C1CCC(n2/c(=N/C(=O)c3cccc(F)c3)[nH]c3ccc(CO)cc32)CC1,0
3047,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)(O)C1CCN(CCOc2cc3c(cn2)[nH]c(=NC(=O)c2cccc(F)c2)n3[C@H]2CC[C@@H](C(=O)O)CC2)CC1,0
2975,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CNc1ccc(C(=O)/N=c2\[nH]c3cnc(OCCN4CCCCC4)cc3n2C2CCC(C(=O)NC(C)C)CC2)cc1.O=C(O)C(F)(F)F,0
2939,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,O=C(/N=c1\[nH]c2cnc(OCCN3CCCCC3)cc2n1C1CCC(C(=O)O)CC1)c1ccccc1,0
2977,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<,5.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)c3cccc(S(C)(=O)=O)c3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
3042,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,5.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)c3cccc(F)c3)[nH]c3ccc(CO)cc32)CC1,0
1817,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,6180.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(O)C(F)(F)F.O=C1CCc2cccc(c2)Nc2nc(ncc2Cl)Nc2cccc1c2,0
1798,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,6600.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=S1(=O)NCc2cccc(c2)Nc2nc(ncc2Cl)Nc2cccc1c2,0
2010,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (Disssolved in DMSO) against human recombinant wild type ALK upon incubation in presence of 30 uM ATP in 50 mM HEPES, pH 7.0 for 90 mins at RT was determined by HOMOGENEOUS TIME RESOLVED FLUORESCENCE (HTRF) FRET ASSAY",NaN,IC50,nM,=,7434.0,Patent; SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; WO2015/50989; (2015); A2;,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)N(C)C(=O)COc2ccc(F)cc21,0
1854,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,"Inhibitory concentration of compound against human recombinant Anaplastic lymphoma kinase using (0.5 uM) Biotin-KKKGPWLEEEEEAYGWLDF-amide as substrate and in presence of 90 uM ATP upon incubation in 50 mM Tris,pH 7.8 for 2 h at 25 degree C",NaN,IC50,nM,=,8200.0,Patent; INCYTE CORP; WO2010/85597; (2010); A1;,Clc1cnc2nc1NCc1cc(ccc1Br)OCCCc1cccc(c1)N2,0
2151,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound (dissolved in 10% DMSO) against human recombinant ALK upon incubation in 60 mM HEPES/NaOH, pH 7.5 in presence of 1 uM [GAMMA-33P]ATP",human,IC50,µM,=,9.33,"Conference Paper; Lai, Daowan; Yu, Shanjiang; Van Ofwegen, Leen; Totzke, Frank; Proksch, Peter; Lin, Wenhan; Bioorganic and Medicinal Chemistry; vol. 19; 22; (2011); p. 6873 - 6880;",Cc1ccc(O)cc1CC[C@@H]1[C@@H](O)CC[C@]2(C)C([C@H](C)/C=C/CC(C)C)CC[C@@H]12,0
255,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1ccc(-c2ccc(Nc3cc(Nc4ccccc4S(=O)(=O)C(C)C)c(Cl)cn3)c(F)c2)cc1,0
333,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccc(C(N)=O)cc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
332,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C3CCNCC3)c3ccncc23)ncc1Cl,0
330,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1ccc(-c2cc(OC)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2C)cc1,0
254,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,C#Cc1cc(Nc2ncc(C)c(Nc3ccccc3C(=O)NC(C)C)n2)c(OC(C)C)cc1C,0
205,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN1CCC(c2cc(OC(C)C)c(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cn[nH]c4n3)cc2C)CC1,0
204,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCN1CCC(c2cc(OC(C)C)c(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cn[nH]c4n3)cc2C)CC1,0
203,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0
202,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1ccc2nc(Nc3cc(C)c(C4CCN(C)CC4)cc3OC(C)C)nc(Nc3ccccc3S(=O)(=O)C(C)C)c2c1,0
331,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2cccc(C(=O)O)c2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
264,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC2CCC2)cc1C1CCNCC1,0
256,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2C(=O)N(C)C)n1,0
271,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCN(CCO)CC1,0
340,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1,0
339,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(CC(=O)O)C2,0
338,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1-c1nc2ccccc2[nH]1,0
337,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)CN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
336,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(C)(=O)=O)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCNCC1,0
278,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3nc[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1,0
277,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(Cl)c(C(=O)NCCN(C)C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
335,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2cc(F)ccc2S(=O)(=O)C(C)C)n1,0
334,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(-c2cc(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cc[nH]c4n3)c(OC(C)C)cc2C)on1,0
274,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)N(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
273,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(CC(N)=O)CC1)C2=O,0
272,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C2CCN(C)CC2)CC1,0
270,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@H]1CCN(C)C1)C2=O,0
257,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1nc(C2CCNCC2)ncc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
269,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC3CCCC3)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
268,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC3CCC3)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
267,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)N3CCCC3)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
266,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1=CCC(=O)CC1,0
265,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN1CCC(c2cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)cc2C)CC1,0
329,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)CN2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
263,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC3CC3)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
262,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cccnc3n2)c(OC(C)C)cc1C1CCNCC1,0
261,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3ccccc3n2)c(OC(C)C)cc1C1CCN(C)CC1,0
260,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CNC1)C2,0
259,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)CN2CCCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
258,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
201,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC(C)C)n2)cc1C1CCNCC1,0
296,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1ccc(C)cc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1,0
328,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2cc(F)ccc2S(=O)(=O)C(C)C)n1,0
321,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(-c2cc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)c(OC(C)C)cc2C)on1,0
319,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
318,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1ccc(-c2ccc(Nc3cc(Nc4ccccc4S(=O)(=O)C(C)C)c(Cl)cn3)cc2C)cc1,0
304,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)(C)CO)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
66,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1[C@@H]1CCCCN1,0
303,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccccc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
25,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
302,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccncc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
301,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)CCO)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
300,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccccc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
299,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cc3c(cc2F)CNC3=O)ncc1Cl,0
298,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c2cc(Cl)ccc2n1,0
317,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCNCC2)cnc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c(Cl)cn1,0
316,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccc(F)cc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
315,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2cc(Nc3ccccc3S(=O)(=O)C(C)C)c(Cl)cn2)ccc1-c1cccc(S(C)(=O)=O)c1,0
51,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCO)CC1,0
50,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCCNC1,0
314,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c2cc(C)ccc2n1,0
297,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1nc(-c2ccccc2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
313,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1ccc2nc(C(N)=O)cc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c2c1,0
312,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2ccc(C3CCNCC3)cc2OC(C)C)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
311,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1cc[nH]n1,0
44,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(C)CC1)C2,0
310,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1nc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
309,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2ccc(C3CCN(C)CC3)cc2OC(C)C)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
308,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COC(=O)C(C)(C)c1ccc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)c1,0
320,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
78,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C,0
327,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccc(N(C)C)c(C)c2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
79,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,C#Cc1cc(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C,0
326,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCNCC2)cnc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c(C#N)cn1,0
325,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCN1CCC(c2cnc(Nc3cc(Nc4ccccc4S(=O)(=O)C(C)C)c(Cl)cn3)c(OC(C)C)c2)CC1,0
324,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCC(=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
323,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1cc(CO)no1,0
322,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1,0
96,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@@H]1CN[C@H](C(N)=O)C1)C2,0
305,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1ccc2c(c1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC2=O,0
95,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCCCN1,0
94,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCNCC1,0
89,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(CC(N)=O)CC1)C2,0
88,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCOC(=O)N1CCC(N2Cc3cc(OC(C)C)c(Nc4ncc(Cl)c(Nc5ccccc5S(=O)(=O)C(C)C)n4)cc3C2=O)CC1,0
87,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(C(=O)N(C)C)CC1)C2,0
86,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1cnn(CCN2CCOCC2)c1,0
85,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(C)CC1)C2=O,0
342,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CONC(=O)c1cc(-c2cc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c(OC(C)C)cc2C)on1,0
84,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC2CCNCC2)c(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1cnn(C)c1,0
83,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCC(N(C)C)CC1,0
82,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1C1CCNCC1,0
81,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1CN1CCOCC1,0
80,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COC(=O)c1ccc(-c2cc(OC)c(Nc3cc(Nc4ccccc4S(=O)(=O)C(C)C)c(Cl)cn3)cc2C)cc1,0
341,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2ccc(C3CCN(CCO)CC3)cc2OC(C)C)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
368,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1ccc(N2CCN(C)CC2)nc1,0
343,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCCN(C)C1,0
405,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1cc(C(=O)NCCN2CCOCC2)no1,0
713,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCNC(=O)N1CCC(N2Cc3cc(OC(C)C)c(Nc4ncc(Cl)c(Nc5ccccc5S(=O)(=O)C(C)C)n4)cc3C2=O)CC1,0
714,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1=CCC(N[C@H](C)CO)CC1,0
433,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N3CCCC3)n2)c(OC(C)C)cc1[C@H]1CC[C@H](N(C)C)CC1,0
715,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1=CCC(N2CCN(C)CC2)CC1,0
716,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1=CC[C@H](N2CCN(C)CC2)CC1,0
432,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@@H](N(C)C)CC1,0
2935,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<=,10.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2c(N)nc3cnc(OCCN4CCCCC4)cc32)CC1,0
409,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C(=O)O,0
408,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(N)(=O)=O)n2)c(F)cc1C1CCN(C)CC1,0
407,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(N)(=O)=O)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
406,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N3CCCC3)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
404,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2cc3c(cc2OC(C)C)Cc2c(CNC4CCNCC4)n[nH]c2-3)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
393,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(CC(N)=O)CC1,0
403,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(CCC#N)CC1)C2=O,0
402,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C2CCN(C)CC2)CC1,0
401,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(CCO)CC1)C2=O,0
400,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(CCC(N)=O)CC1,0
399,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@H]1C[C@@H](C(N)=O)N(C)C1)C2,0
2273,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(N1CCN(CCC(=O)O)CC1)C2,0
398,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@H]1CN[C@H](C(=O)O)C1)C2,0
397,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(CCC(=O)O)CC1,0
396,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2cc3c(cc2OC(C)C)Cc2c(CN4CCOCC4)n[nH]c2-3)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
2974,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,anaplastic lymphoma kinase (ALK); inhibition ofanaplastic lymphoma kinase (ALK) of human,NaN,IC50,µM,<=,10.0,Patent; AMGEN INC; WO2012/18668; (2012); A1;,CC(C)NC(=O)C1CCC(n2/c(=N/C(=O)C3CCCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1.O=C(O)C(F)(F)F,0
395,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@H]1CCN(CCO)C1)C2=O,0
712,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1ccc(S(=O)(=O)C(C)C)c(Nc2nc(Nc3cc4c(cc3OC(C)C)CN(C3CCN(C)CC3)C4=O)nc3[nH]ncc23)c1,0
711,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCC(N2CCNC(=O)C2)CC1,0
710,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n1)C(=O)N(C1CCN(C)CC1)C2,0
434,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2cc(C)c([C@H]3CC[C@H](N(C)C)CC3)cc2OC(C)C)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
2219,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,NaN,In Vitro (Efficacy),NaN,"Inhibitory concentration of the compound against recombinant human Anaplastic lymphoma kinase (0.25 nM) using 0.5 uM biotinylated peptide substrate (Biotin-KKKGPWLEEEEEAYGWLDF-amide) upon incubation in presence of 90 uM ATP in 50 mM Tris, pH 7.8 for 2 hrs at 25 degree C by HTRF assay",human,IC50,nM,=,10000.0,Patent; INCYTE CORP; US2009/286778; (2009); A1;,O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)c1ccccn1.O=C(O)C(F)(F)F,0
698,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)cnc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c(Cl)cn1,0
699,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1nc(-c2cc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)c(OC(C)C)cc2C)c[nH]1,0
700,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C(C)CN(C)CCO,0
701,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(CCO)C2,0
702,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C)CC2)ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2nc[nH]c2n1,0
703,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(N1CCOCC1)C2,0
704,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCOC(=O)c1n[nH]c2c1Cc1cc(OC(C)C)c(Nc3ncc(C)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)cc1-2,0
705,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@@H](N(C)C)C[C@@H]1N(C)C,0
706,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1ccc(-c2cc(OC)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N4CCOCC4)n3)cc2C)cc1,0
443,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2cc(C)c([C@H]3CC[C@@H](N(C)C)CC3)cc2OC(C)C)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
707,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)NCCN3CCN(C)CC3)nc3ccccc23)ncc1Cl,0
442,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@H](N(C)C)CC1,0
441,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)(CO)CO)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
440,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCCCN2C)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
439,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN1CCC(N2Cc3cc(OC(C)C)c(Nc4nc(Nc5cc(C)ccc5S(=O)(=O)C(C)C)c5cn[nH]c5n4)cc3C2=O)CC1,0
708,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)C1CCC(c2cc(OC(C)C)c(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cc[nH]c4n3)cc2C)CN1,0
306,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2ncc(C3CCNCC3)cc2OC(C)C)cc1Nc1ccccc1S(C)(=O)=O,0
438,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@H](N2CCCC2)CC1,0
709,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n1)C(=O)N(C1CCNCC1)C2,0
437,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCCS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C)c(C3CCN(C)CC3)cc2OC(C)C)ncc1Cl,0
436,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CN[C@H]1CC[C@H](c2cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)cc2C)CC1,0
435,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@@H](N(C)C)CC1,0
394,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(CCCO)CC1,0
392,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1CCN1CCN(C)CC1,0
344,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1-c1cc(C)n[nH]1,0
355,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(CC(N)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
364,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1ccc(S(=O)(=O)C(C)C)c(Nc2nc(Nc3cc(C)c(C4CCCCN4)cc3OC(C)C)nc3[nH]ncc23)c1,0
363,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C(C)C)CC1,0
362,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1C(=O)NC1CCN(C)CC1,0
361,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1ccc(-c2cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2C#N)cc1,0
360,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3nc[nH]c3n2)c(OC(C)C)cc1C1CCC(N(C)C)CC1,0
1067,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@@H](N2CCN(C)CC2)CC1,0
359,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccc(C(=O)NC3CC3)cc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
358,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccc(N3CCOCC3)cc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
3040,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,10.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)CN1CCC(n2c(=NC(=O)c3ccccc3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
357,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)NC3CCNCC3)nc3ccccc23)ncc1Cl,0
356,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC(C)C)cc1-c1ccnc(F)c1,0
354,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC2CCN(C)CC2)cc1-c1ccncc1,0
391,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc2nc(Nc3cc(C)c(C4CCN(C)CC4)cc3OC(C)C)nc(Nc3ccccc3S(=O)(=O)C(C)C)c2cc1OC,0
353,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCOCC1)C2,0
352,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCN(CC)Cc1cc(-c2cc(Nc3ncc(C)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)c(OC(C)C)cc2C)on1,0
749,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc([C@H]2CC[C@@H](N(C)C)CC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
748,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN(C)[C@H]1CC[C@@H](c2cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)cc2C)CC1,0
351,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C(C)(C)CN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
350,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(CCO)CC2)cnc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c(Cl)cn1,0
349,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCCCN1,0
348,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCCNC1,0
347,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N2CCCC2)n1,0
346,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1nc(-c2ccc(N3CCNCC3)cc2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
345,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)N3CCC3)n2)c(OC(C)C)cc1C1CCN(C)CC1,0
365,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN(C)C1CCC(c2cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)cc2C)CC1,0
366,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCN1CCC(c2cc(OC(C)C)c(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cc[nH]c4n3)cc2C)CC1,0
367,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c3c([nH]c(=O)c2cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)CN(C)CC3,0
369,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0
390,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCC(N2CCN(C)CC2)CC1,0
2988,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,NaN,NaN,In Vitro (Efficacy),NaN,enzyme activity; inhibition ofrecombinant N-terminal GST-fused wild-type ALK cytoplasmic domain of humanALK: anaplastic lymphoma kinase; inhibitory concentration (IC),NaN,IC50,µM,<=,10.0,Patent; GLAXOSMITHKLINE PLC; WO2013/74518; (2013); A1;,CC(C)NC(=O)[C@H]1CC[C@@H](n2c(=NC(=O)C3CCCCC3)[nH]c3cnc(OCCN4CCCCC4)cc32)CC1,0
389,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(CC(=O)O)CC1,0
388,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n1)C(=O)N(C1CCNCC1)C2,0
387,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@@H]1CN3CCC1CC3)C2,0
386,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN1CCCC(c2cc(OC(C)C)c(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cc[nH]c4n3)cc2C)C1,0
385,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCCN(CCO)C1,0
384,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(CCO)CC1,0
1037,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@@H]1CCCN(CCO)C1)C2,0
383,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(C1CCN(C(C)C)CC1)C2,0
382,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C(=O)N(C)C)CC1,0
381,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)C(C)C)n2)CCCN3)c(OC(C)C)cc1C1CCNCC1,0
380,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C(C)CO)CC1,0
379,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COCCN1CCC(c2cc(OC(C)C)c(Nc3nc(Nc4ccccc4S(=O)(=O)C(C)C)c4cc[nH]c4n3)cc2C)CC1,0
378,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,COc1cc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)N(C)C)n1,0
377,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CCOC(=O)c1n[nH]c2c1Cc1cc(OC(C)C)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3)cc1-2,0
376,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N([C@@H]1CCCNC1)C2,0
375,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(OC(C)C)c(Nc2ncc(C)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1-c1ccc(N2CCNCC2)nc1,0
374,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1[C@H]1CC[C@H](N(C)C)C[C@@H]1N(C)C,0
373,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C(=O)NCCN3CCOCC3)nc3ccccc23)ncc1Cl,0
372,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)C(=O)N(CCN1CCCC1)C2,0
371,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CC(C)Oc1cc(C2CCN(CCO)CC2)ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2nc[nH]c2n1,0
370,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,CNC(=O)c1ccc(-c2cc(OC)c(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)NC4CCC4)n3)cc2C)cc1,0
307,ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human],ALK tyrosine kinase receptor [human]:Wild,human,Inhibitor,inhibitory activity,In Vitro (Efficacy),NaN,In vitro inhibitory activity against growth of mouse BaF3 cells expressing human NPM fused ALK; Range is 1 nM to 10 uM,NaN,IC50,µM,=,10.0,Patent; NOVARTIS AG; Novartis (w/o Sandoz); WO2008/73687; (2008); A2;,Cc1cnc(Nc2cc3c(cc2OC(C)C)CCC3=O)nc1Nc1ccccc1S(=O)(=O)C(C)C,0
